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1. Abstract  
 
Gastric adenocarcinoma carries a poor prognosis in part due to the late stage of diagnosis. Risk 
factors include H. pylori infection, family history of gastric cancer, in particular hereditary 
diffuse gastric cancer and pernicious anaemia. The stages in the progression to cancer include 
chronic gastritis, gastric atrophy (GA), intestinal metaplasia (GIM) and dysplasia. The key to 
early detection of cancer and improved survival is to non-invasively identify those at risk prior 
to endoscopy. However, although biomarkers may help in the detection of patients with chronic 
atrophic gastritis (CAG), there is insufficient evidence to support their use for population 
screening. High quality endoscopy with full mucosal visualisation is an important part of 
improving early detection. Image enhanced endoscopy combined with biopsy sampling for 
histopathology is the best approach to detect and accurately risk stratify GA and GIM. Biopsies 
following the Sydney protocol from the antrum, incisura, lesser and greater curvature allow 
both diagnostic confirmation and risk stratification for progression to cancer. Ideally biopsies 
should be directed to areas of GA or GIM visualised by high quality endoscopy. There is 
insufficient evidence to support screening in a low risk population (undergoing routine 
diagnostic OGD) such as the UK, but endoscopic surveillance every three years should be 
offered to patients with extensive GA or GIM. Endoscopic mucosal resection (EMR) or 
endoscopic submucosal dissection (ESD) of visible gastric dysplasia and early cancer has been 
shown to be efficacious with a high success rate and low rate of recurrence, providing specific 
quality criteria are met.  
 
 
 
2. Executive Summary 
 
Gastric adenocarcinoma continues to be a frequent cause of death in the world and is the 16th 
most common cancer in the UK. The most common stages in the progression to gastric 
adenocarcinoma are GA and GIM which are collectively known as CAG. These conditions are 
principally caused by H. pylori infection and less commonly by autoimmune gastritis. The key 
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to having a significant impact on the prognosis of gastric adenocarcinoma and its economic 
burden is to accurately identify individuals at greatest risk and intervene prior to them 
establishing cancer through recognised efficacious therapies, including endoscopic resection. 
The BSG endoscopy committee agreed to create a guideline to provide statements and 
recommendations on the prevalence, risks, diagnosis, treatment, surveillance, and screening of 
gastric pre- and early gastric malignant lesions. The principal patient group are those found to 
have GA, GIM, gastric epithelial dysplasia or early gastric adenocarcinoma limited to the 
mucosal or superficial submucosal layers. The target users include gastroenterologists, 
gastrointestinal surgeons, pathologists, endoscopists and general practitioners. We followed 
The Appraisal of Guidelines for Research and Evaluation (AGREE  II) Instrument and the 
quality of the evidence was assessed following The Grading of Recommendations, 
Assessment, Development, and Evaluation (GRADE) System. 
 
A series of statements, recommendations and suggestions are proposed to ensure that there is 
consistency of practice such that patients with gastric pre- and early gastric malignant lesions 
are provided with optimal care. These recommendations are listed below: 
 
 
1. We recommend H. pylori eradication to reduce the risk of gastric 
adenocarcinoma development in patients who have gastric atrophy (Evidence 
level: High quality; Grade of recommendation: high; Level of agreement: 100%) 
 
2. We suggest that H. pylori eradication may be of some benefit to reduce the risk 
of developing gastric adenocarcinoma in those who already have H. pylori-
associated gastric intestinal metaplasia, dysplasia or cancer. (Evidence level: High 
quality; Grade of recommendation: weak; Level of agreement: 100%)  
 
3. We do not recommend the use of biomarkers as a screening tool in areas with a 
low incidence of gastric adenocarcinoma, such as the UK. (Evidence level: Low 
quality; Grade of recommendation: weak; Level of agreement: 93%) 
 
4. We recommend patients at higher risk for gastric adenocarcinoma, including 
gastric atrophy and gastric intestinal metaplasia should undergo a full 
systematic endoscopy protocol of the stomach with clear photo documentation of 
gastric regions and pathology. We suggest a minimum examination time of 7 
minutes. (Evidence level: moderate quality; Grade of recommendation: strong; Level 
of agreement: 100 %) 
 
5. Gastric atrophy and intestinal metaplasia may be detectable by white light 
endoscopy alone, however the accuracy is poor. Therefore, we do not 
recommend establishing a diagnosis or risk-stratification using white light 
endoscopy alone. (Evidence level: moderate quality; Grade of recommendation: 
strong; Level of agreement: 93%) 
 
6. We recommend image-enhanced endoscopy is the best imaging modality to 
accurately detect and risk-stratify gastric atrophy and gastric intestinal 
metaplasia (Evidence level: moderate quality; Grade of recommendation: strong; 
Level of agreement: 100%) 
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7. We recommend that endoscopic appearances on white light endoscopy suggestive 
of gastric atrophy or gastric intestinal metaplasia require escalation to high 
resolution, image-enhanced endoscopy and, where available, magnification 
endoscopy (Evidence level: low quality; Grade of recommendation: strong; Level of 
agreement: 100%) 
 
8. We recommend that the location and extent of gastric atrophy and gastric 
intestinal metaplasia should be clearly documented with photo-evidence. 
Endoscopic grading should be documented as distal gastric (affecting antrum or 
incisura - low risk) or proximal gastric (affecting the corpus with or without the 
antrum and incisura - high risk). (Evidence level: low quality; Grade of 
recommendation: strong; Level of agreement: 93%)  
 
9. We recommend that patients with image-enhanced features of chronic atrophic 
gastritis should undergo biopsies for confirmation of endoscopic diagnosis; 
biopsies are directed at mucosal sites within Sydney protocol areas where 
enhanced imaging reveals gastric intestinal metaplasia. Biopsies should be 
collected in separate containers and labelled as either ‘directed' or ‘random’ to 
corroborate endoscopic staging assessment (Evidence level: low quality; Grade of 
recommendation: strong; Level of agreement: 93%) 
 
10. We recommend that endoscopic appearances on white light endoscopy of gastric 
dysplasia and early gastric cancer (differences in colour, loss of vascularity, 
slight elevation or depression, nodularity, thickening, and abnormal convergence 
or flattening of folds) require escalation to image-enhanced endoscopy and, 
where available, magnification endoscopy (Evidence level: low quality; Grade of 
recommendation: strong; Level of agreement: 100%) 
 
11. We recommend image-enhanced endoscopy is the best imaging modality to 
accurately diagnose and stage gastric dysplasia and early gastric cancer 
(Evidence level: moderate quality; Grade of recommendation: strong; Level of 
agreement: 100%) 
 
12. We suggest that a baseline endoscopy with biopsies should be considered in 
individuals 50 years and over, with laboratory evidence of pernicious anaemia, 
defined by vitamin B12 deficiency and either positive gastric parietal cell or 
intrinsic factor antibodies. As gastric atrophy affects the corpus in pernicious 
anaemia, biopsies should be taken from the greater and lesser curves (Evidence 
level: low quality; Grade of recommendation: weak; Level of agreement: 93%)  
 
13. We recommend endoscopic surveillance every 3 years should be offered to 
patients diagnosed with extensive gastric atrophy or gastric intestinal metaplasia 
defined as that affecting the antrum and body (Evidence level: low quality; Grade 
of recommendation: strong; Level of agreement: 100%) 
 
14. We do not recommend surveillance in patients with gastric atrophy or gastric 
intestinal metaplasia limited just to the gastric antrum unless there are 
additional risk factors such as a strong family history of gastric cancer or 
persistent H. pylori infection, then we suggest 3 yearly surveillance. (Evidence 
level: low quality; Grade of recommendation: strong; Level of agreement: 93%) 
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15. We recommend patients with non-visible low-grade dysplasia should undergo a 
second endoscopy with enhanced imaging and extensive biopsy sampling, 
followed by a repeat endoscopy within 1 year if no visible neoplasia is detected. If 
there is persistent, non-visible low-grade dysplasia, endoscopy should be 
repeated annually thereafter. (Evidence level: low quality; Grade of 
recommendation: strong; Level of agreement: 100%) 
 
16. We recommend patients with non-visible high-grade dysplasia should undergo a 
second endoscopy with enhanced imaging and extensive biopsy sampling. We 
recommend on-going surveillance at 6-monthly intervals for persistent, non-
visible high-grade dysplasia. High grade dysplasia should be discussed at the 
regional upper GI cancer MDT and referred to a clinician with the appropriate 
expertise. (Evidence level: low quality; Grade of recommendation: strong; Level of 
agreement: 100%)  
 
17. We recommend that all gastric dysplasia and early gastric adenocarcinoma 
should be resected in an en-bloc fashion (EMR technique can achieve en-bloc 
excision for lesions ≤10mm in size but only ESD technique can ensure en-bloc 
excision for lesions >10mm in size) (Evidence level: high quality; Grade of 
recommendation: strong; Level of agreement: 100%) 
 
18. We recommend that complete (R0) endoscopic resection of gastric dysplasia and 
early gastric adenocarcinoma with the following features should be considered as 
curative: 
1) Low-grade dysplasia 
2) High-grade dysplasia 
3) Well or moderately differentiated intramucosal adenocarcinoma, irrespective 
of size and without ulceration 
4) Well or moderately differentiated intramucosal adenocarcinoma, <3.0 cm in 
size if ulcerated 
5) Well or moderately differentiated submucosal adenocarcinoma, <3.0 cm in 
size, with superficial submucosal invasion (Sm1; <500 micron submucosal 
invasion as measured in a straight line from the deepest fibre of the muscularis 
mucosae)  
6) Poorly differentiated intramucosal adenocarcinoma, ≤2.0 cm in size (Evidence 
level: moderate quality; Grade of recommendation: strong; Level of agreement: 93%) 
 
19. The histopathological features of early gastric adenocarcinoma associated with a 
higher risk of lymph node metastasis after endoscopic resection include: 
1) Poorly differentiated submucosal cancer, irrespective of invasion depth below 
muscularis mucosae 
2) Signet ring cancer 
3) Lympho-vascular invasion 
4) Depth of submucosal invasion ≥500 microns as measured in a straight line 
from the deepest fibre of the muscularis mucosae (Evidence level: moderate 
quality; Grade of recommendation: strong; Level of agreement: 93%)  
 
20. We do not recommend the use of NSAIDs or cyclooxygenase-2 (COX-2) 
inhibitors to reduce the risk of progression of pre-malignant lesions of the 
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stomach.  (Evidence level: Moderate; Grade of recommendation: Strong; Level of 
agreement 100%) 
 
21. We do not recommend the use of antioxidants as a means to reduce the 
prevalence of pre-malignant gastric lesions. (Evidence level: Moderate; Grade of 
recommendation: Strong; Level of agreement 100%)  
 
22. We suggest endoscopic screening should be considered in individuals aged 50 or 
older with multiple risk factors for gastric adenocarcinoma (males, smokers, 
pernicious anaemia), in particular those with a first degree relative with gastric 
cancer. (Evidence level: low quality; Grade of recommendation: weak; Level of 
agreement: 100%) 
 
23. We do not recommend endoscopic screening for gastric adenocarcinoma in the 
UK population (Evidence level: low quality; Grade of recommendation: strong; 
Level of agreement: 100%) 
 
24. We recommend that the number of gastric polyps (or estimated number), 
location of polyps, and size of the largest polyp should be clearly documented 
(Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 
100%) 
 
25. We recommend that gastric polyps other than fundic gland polyps should be 
biopsied for histopathological assessment (Evidence level: low quality; Grade of 
recommendation: strong; Level of agreement: 100%) 
 
26. We recommend that photo-documentation should be undertaken for all polyps 
or representative polyps if numerous (Evidence level: low quality; Grade of 
recommendation: strong; Level of agreement: 100%) 
 
27. We recommend that if adenomas or hyperplastic polyps are present, the 
background mucosa should be endoscopically assessed for gastric atrophy, 
gastric intestinal metaplasia, H. pylori, and synchronous neoplasia (Evidence 
level: moderate quality; Grade of recommendation: strong; Level of agreement: 
100%) 
 
28. We recommend that all adenomas should be resected when clinically 
appropriate and safe to do so (Evidence level: low quality; Grade of 
recommendation: strong; Level of agreement: 100%) 
 
29. We recommend that a follow up gastroscopy should be performed at 12 months 
after complete endoscopic excision of adenomas, then on-going surveillance 
gastroscopy annually when appropriate (Evidence level: low quality; Grade of 
recommendation: strong; Level of agreement: 93%) 
 
30. We suggest that hyperplastic polyps >1cm, pedunculated morphology, and those 
causing symptoms (obstruction, bleeding) should be resected. If present, H. 
pylori should be eradicated prior to re-evaluation for endoscopic therapy 
(Evidence level: low quality; Grade of recommendation: weak; Level of agreement: 
100%) 
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31. We suggest enhanced endoscopic imaging is used to aid characterisation of 
gastric polyps when there is diagnostic uncertainty following white light 
examination (Evidence level: low quality; Grade of recommendation: weak; Level of 
agreement: 93%) 
 
Three pathways have been created to allow a quick reference to the management of CAG, 
gastric dysplasia and gastric epithelial polyps (Figure 1). 
 
3. Background 
 
Gastric adenocarcinoma is a major cause of cancer mortality worldwide (1–3). In the UK in 
2016, there were 5,314 cases of gastric cancer which has been declining gradually with the 
incidence of H.pylori infection. Although there has been a decline in the incidence over the last 
50 years, recent studies have demonstrated an increasing incidence of gastric adenocarcinoma 
among young white people in the US, alongside a Swedish study demonstrating an increasing 
incidence of pre-malignant gastric lesions among adults aged 35-44 years (4,5). These studies 
may suggest that historically declining gastric adenocarcinoma incidence rates may alter. At 
present within the UK, gastric cancer is the 16th most common cancer, within Europe it is the 
6th most common cancer, and worldwide it is the 5th most common (1–3).  Importantly, with 
the exception of Japan and South Korea, the majority of gastric cancers worldwide are 
diagnosed at a late stage resulting in poor prognosis with a 29% average 5-year survival (3,6). 
The UK all stage average 5-year survival rate is 18%, compared to an 80% average 5-year 
survival for stage 1A (3). Clearly, Japan’s earlier stage of diagnosis and superior 5-year 
survival highlights the need for earlier recognition and treatment to overcome this bleak 
prognosis (7). 
 
The key to having a significant impact on the prognosis of gastric cancer and its global 
economic burden is to accurately identify the individuals who are at greatest risk and intervene 
prior to gastric cancer development through recognised efficacious therapies, including 
endoscopic resection. The canonical model for cancer progression in the stomach is the Correa 
sequence which outlines a stepwise linear progression from chronic gastritis through GA, GIM, 
dysplasia, and finally invasive cancer (8). This model was amended to involve the role of H. 
pylori as the prime causative environmental agent (9) and has remained the dominant model 
since. Diagnosis and surveillance of higher risk patients in this cascade has been proposed as a 
strategy to reduce the mortality and morbidity of gastric adenocarcinoma. 
 
The first international guidelines on the Management of Precancerous conditions and Lesions 
in Stomach (MAPS) were published in 2012 by an international guidelines development group 
(10). These have not yet been revised. There is significant heterogeneity of practice in regards 
to the management of pre- and early malignant gastric lesions in the UK, partly because few 
endoscopists follow the MAPS guidance.  
 
 
4. Objectives 
 
The objectives of these guidelines are to summarise the current evidence base and to provide 
recommendations on the diagnosis, risks, and management of gastric pre- and early malignant 
lesions including GA, GIM, dysplasia and early adenocarcinoma. These guidelines are 
intended for the UK population. 
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5. Methodology 
 
The guideline was commissioned by the BSG in May 2015 and the proposal approved by 
Clinical Standards and Services Committee. The guideline was developed in line with the BSG 
Guideline Process (11). The purpose of the guideline was to provide guidance to healthcare 
professionals who are involved in the care of patients at risk of gastric cancer, including 
gastroenterologists, gastrointestinal surgeons, pathologists, endoscopists and general 
practitioners. The Appraisal of Guidelines for Research and Evaluation (AGREE  II) 
Instrument  (May 2009) (12) was used to guide the methodology. The chair (MRB) convened 
a guideline development group (GDG), consisting of clinicians and patients with experience 
of, or in the management of these conditions. Members of the GDG were selected to ensure 
the relevant professional bodies and specialities were represented including 
gastroenterologists, surgeons and pathologists. GDG members were required to declare any 
conflict of interests (COI). The scope and purpose of the guidelines were initially discussed by 
the GDG on 20th July 2015 at the first consensus meeting, following which a set of key 
questions were created. The key questions were sub-divided into clinical groups including 
diagnosis, treatment, surveillance, screening, and research (Table 1). The GDG then voted 
anonymously on the relevance of each question to the guidelines and those with less than 75% 
agreement were excluded. The GDG then met in London on 17th September 2015 for a second 
consensus meeting to discuss the agreed key questions, agree on methodology, and allocate 
leads and sub-groups to each question.  Each lead and subgroup formulated a set of clinical 
questions pertinent to each key question using the PICO (Patients, Interventions, Controls and 
Outcomes) system, within which these four critical components were pre-defined as precisely 
as possible. The importance of each PICO outcome was ranked numerically by the sub-groups 
on a 1 to 9 scale (7 to 9 – critical; 4 to 6 – important; 1 to 3 – of limited importance) according 
to the clinical importance of each. Those 3 or less were excluded. 
 
Table 1 
Key questions, sub-groups and leads 
 
Question Lead Sub-group 
Diagnosis: overview 
What are the epithelial glandular pre-
cancerous lesions of the stomach, what is 
their prevalence within the UK and what 
risk do they incur ? 
Dr David 
Graham 
Matthew Banks, Ernst 
Kuipers, Mario Dinis-
Ribeiro, Marnix Jansen, 
Marco Novelli, Manuel 
Rodriguez-Justo, Neil 
Shepherd 
Are there groups of individuals (Without 
known pre-cancerous lesions) known to be 
at increased risk of glandular gastric cancer 
e.g. Family history, ethnic origin, genotype 
and phenotype ?  
Dr 
Massimiliano 
di Pietro 
Matthew Banks, Sergio 
Coda, David Graham, 
Noriya Uedo 
Who should be screened for helicobacter 
pylori to reduce gastric cancer and how 
should they be screened? Does eradication 
prevent progression to glandular gastric 
cancer ?  
Prof Mark 
Pritchard 
Matthew Banks, Takuji 
Gotoda, Ernst Kuipers, 
David Graham 
 9 
What blood tests are useful in the 
management of pre-cancerous gastric 
lesions? Can they be applied for population 
screening, monitoring those at risk or those 
with known lesions ?  
Dr David 
Graham 
Matthew Banks, Mario 
Dinis-Ribeiro, Mark 
Pritchard 
Diagnosis: Endoscopy 
Outside the recommendations within the 
UK guidelines for the quality of endoscopy 
are there further processes that are 
suggested for the detection and diagnosis 
of pre or early malignant lesions of the 
stomach ? 
Prof Takuji 
Gotoda 
Matthew Banks, Krish 
Ragunath, David Graham, 
Sergio Coda 
How does one identify pre or early 
malignant lesions and ensure accurate 
documentation when reporting? Is a station 
based approach beneficial and are there 
mucosal features that identify these lesions 
(including recognizing the atrophic 
border)? 
Mr Sergio 
Coda 
Matthew Banks, Takuji 
Gotoda, Noriya Uedo, 
Pradeep Bhandari, Krish 
Ragunath, David Graham 
What biopsy strategy should be adopted 
for the sampling and reporting of the pre- 
or early malignant stomach? Should all 
those undergoing routine endoscopy be 
biopsied or are there groups to target ?  
 
Dr Marnix 
Jansen 
Matthew Banks, David 
Graham, Sergio Coda, 
Marco Novelli, Manuel 
Rodriguez-Justo, Neil 
Shepherd 
What histopathogical and imaging 
modalities are suggested for the staging of 
glandular pre- and early gastric malignant 
lesions of the stomach ? 
Mr Sergio 
Coda 
Marnix Jansen, Matthew 
Banks, David Graham, 
Sergio Coda, Marco Novelli, 
Manuel Rodriguez-Justo, 
Neil Shepherd 
Surveillance 
Should individuals with pre- malignant 
gastric glandular lesions undergo 
surveillance? If so, what are the 
recommendations? 
Dr Matthew 
Banks 
Mario Dinis-Ribeiro, David 
graham, Massimiliano di 
Pietro, Ernst Kuipers 
Treatment: Endoscopy 
What lesions are amenable for endoscopic 
removal? How should these lesions be 
removed? Are there criteria on 
histopathological assessment that 
determine prognosis and follow up?  
Prof Pradeep 
Bhandari 
Matthew Banks, Krish 
Ragunath, Takuji Gotoda, 
Noriya Uedo, David 
Graham. 
Treatment: Pharmacological 
Is there a role for other pharmacological 
therapies e.g. COX inhibitors and anti-
oxidants ? 
Dr David 
Graham 
Matthew Banks 
Screening 
Is there evidence to support the 
introduction of a population screening 
programme for glandular gastric cancer? 
Dr Matthew 
Banks 
Mark Pritchard, David 
Graham 
 10 
Gastric polyps 
What are the epithelial gastric polyps and 
how should they be managed ? 
Dr Matthew 
Banks 
Sergio Coda, Mark 
Pritchard, Pradeep Bhandari 
Research   
Are there recommendations for future 
research into the diagnosis and 
management of pre- and earl malignant 
lesions of the stomach ?  
Dr Matthew 
Banks 
Marnix Jansen, David 
Graham 
 
 
 
Literature searches, evidence synthesis and grading of evidence 
 
A literature search was undertaken by each sub-group with pre-defined search terms, electronic 
databases utilised (Pubmed, Embase, Cochrane and Medline), and the time period covered. 
Where appropriate, conference abstracts were used to help formulate recommendations, 
provided that these were of sufficient scientific rigour.  
 
The PICOs were used to guide the search for evidence and the highest quality studies were 
prioritised. Systematic reviews or meta-analyses were selected initially. Where systematic 
reviews, meta-analyses, or critically-appraised articles were unavailable, lower levels of 
evidence were selected. Where reviews utilise poor quality studies such as that by Spence et al 
(13), for example where the review was based upon small, often single centre cohort studies 
resulting in high levels of heterogenicity, this is discussed in the evidence review and 
highlighted in the evidence tables. In this instance, more weight is given to larger studies 
utilising large databases, which are likely to be more accurate. This hierarchy of searching was 
performed in a pyramidal sequence from top (High quality) to bottom (Low quality) cascading 
from recently published systematic reviews of RCTs or observational studies; to RCTs; and 
subsequently to observational studies providing no evidence is available from the higher 
quality categories. The selected evidence was tabulated in evidence table categorising each 
study into the study design, intervention/clinical question, participants/Population, reference 
standard, results and conclusions/Comments. 
 
Although randomised controlled studies are deemed the most appropriate type of study to 
assess the effectiveness of an intervention, other types of studies were included to assess types 
of effectiveness, such as ways of delivering service or outcomes from registries in clinical 
practice. If evidence from studies was weak or contradictory, searches for alternative sources 
were undertaken to see if the evidence concurred or contradicted (triangulation of searches). 
All available negative studies were included in the searches. The subgroups discussed the 
external validity of the studies and whether the study outcomes are applicable to the target 
population for the guidelines. Literature searches were transparent and reproducible to reduce 
‘dissemination biases’. 
 
All evidence tables and references were downloaded to a shared reference manager (F1000 
Workspace), to which all GDG members had access. Shortly before the statements were 
finalised, a further literature search was undertaken. The quality of the evidence was assessed 
following The Grading of Recommendations, Assessment, Development, and Evaluation 
(GRADE) terminology using table 2 (14). Evidence is graded as high, moderate, low, and very 
low quality (Table 2). 
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The body of evidence for many questions was of low quality. Thus many statements were based 
on the consensus of the GDG given the limitations of the evidence. 
 
Table 2: Evidence level 
Evidence level  
High quality One or more well-designed and well-executed randomized controlled trials 
(RCTs) that yield consistent and directly applicable results 
This level also means that further research is very unlikely to change our 
confidence in the estimate of effect 
Moderate 
quality 
RCTs with important limitations (i.e., biased assessment of the treatment effect, 
large loss to follow-up, lack of blinding, unexplained heterogeneity), indirect 
evidence originating from similar (But not identical) populations of interest, and 
RCTs with very small numbers of participants or observed events. 
In addition, evidence from well-designed controlled trials without 
randomization, from well designed cohort or case-controlled analytic studies, 
and from multiple time series with or without intervention is in this category. 
This level also means that further research will probably have an important 
impact on our confidence in the estimate of effect and may change the estimate. 
Low quality Observational studies would typically re rated as low quality because of the risk 
for bias.1 
This level also means that further research is very likely to have an important 
impact on our confidence in the estimate of effect and will probably change the 
estimate 
Very low 
quality2 
Evidence is conflicting, of poor quality, or lacking, and hence the balance of 
benefits and harms cannot be determined. 
Any estimate of effect is very uncertain as evidence is either unavailable or does 
not permit a conclusion 
1Quality of evidence based on observational studies may be rated as moderate or even high, depending on 
circumstances under which evidence is obtained from observational studies. Factors that may contribute to 
upgrading the quality of evidence include a large magnitude of the observed effect, a dose-response association, 
or the presence of anobservaed effect when all plausible confounders would decrease the observed effect 
2Insufficient evidence to determine for or against routinely providing a service 
 
 
Recommendations 
 
Recommendations were made by each subgroup pertaining to the PICOs and graded as above 
with the strength of each recommendation. Recommendation strength is based upon 4 factors:  
1. Balance between desirable and undesirable effects (not considering cost) 
2. Quality of the evidence across critical/important outcomes 
3. Patients’ values and preferences 
4. Costs (resource utilisation) 
 
There are 2 grades of recommendations: Strong where the benefits clearly outweigh risks and 
burden (‘We recommend’); Weak where the benefits closely balanced with risks/burden (‘We 
suggest’). 
 
Once consensus was reached within the sub-group, the level of agreement for the 
recommendations was obtained from the whole GDG by anonymised voting. Level of 
agreement was sub-divided into 5 categories: Strongly agree, agree, undecided, disagree, and 
strongly disagree. All comments were used to amend recommendations where appropriate and 
a second round of voting was undertaken for any modifications. All results and comments were 
anonymously sent to the GDG Chairman (MRB). Where the GDG level of agreement was 
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consistently below 90% for strongly agree and agree after three rounds of voting, the 
recommendation was excluded. 
 
 
6. Summary of Statements, Recommendations & Suggestions 
 
6.1 Pathogenesis, diagnosis and epidemiology of pre and early malignant 
gastric lesions 
 
 
6.1.1 Pathogenesis and epidemiology of pre and early malignant gastric lesions 
 
 
What are the pre-cancerous lesions of the stomach, what is their prevalence within the UK, 
and what risk do they confer? 
 
Patients with gastric atrophy &  gastric intestinal metaplasia have an increased risk of 
gastric adenocarcinoma. Increased severity of atrophy & extent of  intestinal metaplasia 
is associated with an increased risk of cancer. (Evidence level: moderate quality; Level of 
agreement: 100%) 
 
Visible low-grade gastric dysplasia has an increased risk of prevalent high-grade 
dysplasia and gastric adenocarcinoma (Evidence level: low quality; Level of agreement: 
100%) 
 
Non-visible low-grade gastric dysplasia increases the risk of gastric adenocarcinoma, 
but the magnitude of this risk is unknown (Evidence level: low quality; Level of 
agreement: 93%) 
 
Gastric high-grade dysplasia carries a significant risk of progression to gastric 
adenocarcinoma (Evidence level: moderate quality; Level of agreement: 100%) 
 
 
Gastric atrophy (GA), gastric intestinal metaplasia (GIM) and dysplasia 
For the purposes of this guideline chronic atrophic gastritis (CAG) collectively includes GA 
and GIM. It is important to define the histopathology of the pre-malignant stomach in order to 
understand progression to cancer and its endoscopic appearances. The normal gastric mucosa 
is divided into two compartments, and includes the gastrin and mucus secreting glands of the 
antrum and the acid and pepsinogen secreting oxyntic glands of the corpus. GA is defined as 
the loss of pre-existent glands native to the gastric compartment. The two phenotypic features 
of GA include the loss of glandular mass with fibrosis of the lamina propria and replacement 
of the native gastric glands by metaplastic or pseudopyloric glands. 
 
The Correa cascade describes the stepwise progression of precursor lesions towards intestinal-
type gastric cancer (9). H. pylori infection initiates the cascade through non-atrophic chronic 
gastritis, GA, GIM, and, finally, dysplasia (15). 
 
Chronic atrophic gastritis encompasses both GA and GIM 
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Gastric atrophy (GA) 
GA is diagnosed histopathologically by two specific features: The presence of chronic 
inflammatory cells, including lymphocytes and plasma cells that expand the lamina propria, 
and the loss of the pre-existent gastric glands.  
 
There is inconsistency in the histopathological diagnosis and severity of GA between 
pathologists resulting in low interobserver agreement by histopathologists when staging GA 
using the OLGA (Operative Link for Gastritis Assessment) Staging System, based upon 
biopsies taken using the Sydney protocol (16,17). Recent studies however, have demonstrated 
that accurate endoscopic staging of the severity of GA are strongly linked to gastric 
adenocarcinoma risk and that the interobserver and intraobserver agreement of endoscopic 
severity assessment, in experienced hands, is moderate to excellent (16,18). 
 
The prevalence of CAG (including GA) worldwide correlates with the prevalence of H.pylori-
associated gastritis, increases with age and tends to be slightly more common in men. 
Prevalence is typically determined utilising gastroscopy and serum pepsinogen. In Western 
populations, the prevalence varies from 0-8.3 % depending upon age (4,19–21). Studies 
performed in high-incidence areas such as Japan and China demonstrated a prevalence of CAG 
of between 33-84% (20,22,23) 
 
Studies exploring the risk of progressing from CAG to gastric adenocarcinoma report a range  
between 0-10% with an annual incidence (person-year) of less than 1% (range 0-1.2%). This 
is regardless of whether the study population is from a high or low-risk area (13,24). This is 
roughly comparable to other pre-malignant conditions of the digestive tract such as Barrett’s 
oesophagus, and colonic adenomatous polyps, where there are established guidelines on 
surveillance. A Swedish observational, population-based, cohort study, reviewing biopsy 
samples of 405,172 patients from 1979 to 2011, demonstrated that 1 in 50 patients with GA 
would develop gastric adenocarcinoma within 20 years (An annual risk of progression of 0.1%) 
(15). A second Dutch study exploring the follow-up data on 22,365 patients diagnosed with 
CAG found the overall annual incidence for the development of gastric cancer in patients with 
GA was 0.1% (25). This increased to 0.25% for GIM, 0.6% for low-grade dysplasia (LGD), 
and 6% for high-grade dysplasia (HGD) within 5 years after diagnosis. A recent systematic 
review found that the annual incidence in most studies varied from 0.1% to 0.5%, but a pooled 
analysis was not undertaken as there was significant heterogeneity between studies (I2 statistic 
of 94%)(13). This is partly explained by the poor quality of evidence in this systematic review 
derived from small cohorts of patients from single centres. 
 
Utilising endoscopic grading, Japanese investigators found the cumulative 5-year incidence of 
gastric adenocarcinoma to be 0.7% in those with no or mild GA upon endoscopic assessment, 
1.9% with GA and 10% in severe endoscopic GA (26). 
 
Gastric intestinal metaplasia (GIM) 
Gastric intestinal metaplasia (GIM) is a common finding in studies of patients undergoing 
diagnostic upper gastrointestinal endoscopy in particular in those with a current or past H. 
pylori infection. GIM prevalence also increases with H. pylori infection, patient age, smokers 
and also with a first-degree relative with gastric cancer. The overall prevalence of GIM in those 
undergoing routine endoscopy varies from 13.8% to 19% in Europe (27,28). It is important to 
point out that the European population is not uniformly representative of that in the UK. For 
example the population studied by Olmez et al are from a high prevalence area of Eastern 
Turkey. A Dutch study found GIM to be present in 25.3% of patients undergoing endoscopy 
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for dyspepsia (29). The prevalence in those infected with H. pylori was 33.9% compared to 
15.2% of those who were not infected. This study also noted that GIM was present in 55% of 
patients with a gastric ulcer and 100% of patients with intestinal type gastric adenocarcinoma. 
A multicentre European study found the prevalence of GIM to be 31.4% in patients infected 
with H. pylori (30). In high-incidence areas such as Japan and China the prevalence of GIM in 
H. pylori infected individuals were 37% and 29.3% respectively (31). GIM was found in only 
2% of those not infected with H. pylori. (15,32).  
 
There is an increased risk of gastric adenocarcinoma in those found to have GIM. 1 in 39 
patients with GIM develop gastric adenocarcinoma within 20 years (15), with similar rates 
found by De Vries et al with an annual incidence of cancer of 0.25% at 5 years (25). A meta-
analysis carried out by Zullo et al in 2000 found that the risk of gastric adenocarcinoma 
progression in those with GIM ranged from 0-10% with this range thought to be due to differing 
study sample sizes and follow-up periods (32). Similarly, a systematic review by Spence et al 
found the annual incidence to range in most studies from 0.15 to 0.4% (13). 
 
The risk of gastric adenocarcinoma varies with the type and extent of GIM. There are three 
histological types of GIM with type I or ‘intestinal’ being termed “complete IM” and types II 
and III or ‘colonic’ termed “incomplete IM”. “Incomplete IM” has been suggested to carry an 
increased cancer risk over “complete IM” (32–34). A Portuguese study demonstrated that 31% 
and 6.9% of those with “incomplete IM” developed LGD and HGD, respectively compared to 
only 8% of those with “complete IM” developing LGD only (35). Therefore, histological 
subtyping may have a role in establishing gastric cancer risk although it should be noted that 
only a minority of patients with invasive gastric cancer seem to have incomplete IM. 
Additionally, it should be noted that the traditional diagnosis of “complete IM” or “incomplete 
IM” is made using enzyme-histochemical staining methods that are highly dependent on the 
individual evaluating them and as such are not reproducible. Therefore, the GDG did not 
consider histological sub-typing for the guidelines. 
 
The extent of the distribution of GIM appears to be of key importance. There are four patterns 
of GIM distribution that have been described (36). The first, “Focal” GIM consists of scattered 
foci, mostly in the lesser curvature and incisura. The second, “Antrum-predominant” GIM, 
involves most of the antrum  and incisura angularis. These two patterns with less extensive 
involvement of the gastric mucosa consist almost exclusively of complete type IM. The third, 
“Magenstraße” GIM spreads throughout the lesser curvature from the cardia to the pylorus, 
also involving the greater curvature of the pre-pyloric antrum. Fourthly, “Diffuse” GIM 
involves the entire gastric mucosa, with the exception of the fundic areas. These more extensive 
types had a greater predominance of “incomplete” GIM.  
 
Several studies have demonstrated that more extensive GIM correlates with increased gastric 
adenocarcinoma risk (32,36–38). Of note, a Columbian study found that when compared to 
focal or antral-predominant GIM, those with Magenstraße GIM had a 5.7-fold increased risk 
of gastric adenocarcinoma, whilst those with a diffuse pattern (antrum and gastric body) had a 
12.2-fold increased risk. Alongside this, an Italian study demonstrated that a >20% extension 
of GIM identified those at increased risk (32). A Japanese study found the cumulative 5-year 
incidence of gastric adenocarcinoma to be 1.5% in those without GIM, compared to 5.3% in 
those with GIM in the antrum only and 9.8% in those with GIM in the antrum and corpus (26). 
 
Unlike the OLGA Staging System, the OLGIM (Operative Link for Gastric Intestinal 
Metaplasia) Staging System, using the presence of GIM, has proven to be a reproducible 
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marker of risk with high interobserver agreement and strong association with OLGA stage 
(39,40). The GDG did not agree that OLGIM should be routinely used in clinical practice, 
although it has practical applicability in research settings. 
 
Intestinal metaplasia of the gastric cardia has been reported to vary from 5% to 25% in those 
having endoscopy(41,42) and may confer an increased risk of dysplasia and cancer although 
the incidence is not clear. Sharma and colleagues found 1/76 patients with prevalent low grade 
dysplasia in cardia intestinal metaplasia (CIM) as defined as that just below the gastro-
oesophageal junction compared to 20/177 having low and high grade dysplasia with short 
segment Barretts Oesophagus (Less then 3cm)(43). 
 
Gastric dysplasia 
The endoscopic prevalence of gastric dysplasia varies from 0.5% to 3.7% in Western countries 
and 9% to 20% in areas with a high incidence of gastric adenocarcinoma (44–47). The 
identification of gastric dysplasia should also alert the endoscopist to the possibility of 
synchronous gastric cancer. Studies have demonstrated the incidence of synchronous gastric 
adenocarcinoma in those with gastric dysplasia to be up to up to 30% (44). 
 
A review of the natural history of gastric dysplasia demonstrated that patients with HGD had 
a rate of malignant progression or synchronous malignant lesions of 60-85% over a median 
interval period of 4 to 48 months (44). In the work by Song et al their observational study found 
that 1 in 19 patients with dysplasia progressed to gastric adenocarcinoma within 20 years, 
although no differentiation was made between those with LGD or HGD (15). De Vries et al 
noted the annual incidence of gastric cancer was 6% in patients with HGD within 5 years (25). 
Of note, it is difficult on histopathology to distinguish between HGD and gastric 
adenocarcinoma from small biopsy samples. 
 
The risk of progression in individuals with LGD is less clear. There is evidence to show that 
LGD will regress in 38-75% of patients and persists in 19-50%. In the LGD lesions that persist, 
the risk of malignant progression ranges from 0-23% in the published literature over 10-48 
months (44). De Vries et al reported that the annual incidence of gastric adenocarcinoma risk 
in those with LGD was 0.6% within 5 years after diagnosis (25).  
 
Visible LGD following resection is upstaged in 25% to 35% of lesions, including those less 
than 1 cm, with an adenocarcinoma rate of 6.9% (44). We have therefore suggested that the 
risk of prevalent HGD or gastric adenocarcinoma is greater in visible LGD. Although there is 
uncertainty with regards to the natural history of non-visible LGD, the evidence suggests that 
there is an increased rate of progression, but the magnitude is currently unclear. 
 
A summary of the risks of gastric cancer can be seen in table 3. 
 
Table 3: The risk of cancer for patients with gastric atrophy and intestinal metaplasia 
 5 year incidence GC (%) Annual incidence (%) 
All GA 1.9 0.1 – 0.5 
Mild GA 0.7  
Severe GA 10  
All GIM  0.15 – 0.4 
0.25 
Antral GIM 5.3  
Antral & corpus GIM 9.8  
 16 
 4 to 48 month interval  
LGD 0 – 23 0.6 
HGD 60 - 85 6 
 
 
6.1.2 Risk factors for gastric adenocarcinoma 
 
Are there groups of individuals (without known pre-cancerous lesions) known to be at 
increased risk of gastric adenocarcinoma ? 
 
There are sub-groups of individuals (other than those with H. pylori infection) who have 
an increased risk of gastric adenocarcinoma. The strongest risk factors include family 
history of gastric adenocarcinoma and serologically confirmed pernicious anaemia with 
gastric atrophy. Additional risk factors include non-White origin, history of gastric 
surgery for benign disease longer than 15 years, age older than 45 years, male sex, high 
salt intake, and smoking (Evidence level: low quality; Level of agreement: 93%) 
 
There are several factors that increase the risk of developing malignant lesions of the stomach, 
which should be taken into account when considering screening on an individual basis. These 
risk factors might help develop larger scale screening programmes in the future and relate to 
multiple sub-categories including patient demographics, epidemiological factors, as well as 
personal, past medical, social, and family history. Unfortunately, the grade of evidence on the 
link between risk factors and gastric cancer development is low, as this comes almost 
universally from retrospective or observational studies, including meta-analyses from these 
studies. The working group has analysed the evidence related to 11 risk factors based on the 
available literature.  
 
Family history appears to be one of the strongest risk factors. Three case-control studies (from 
Japan, Poland and South Korea) for a total of 1,024 gastric cancer cases showed that the odds 
ratio (OR) for gastric adenocarcinoma in first-degree relatives of patients with gastric 
adenocarcinoma ranged from 2.3 to 3.5 (48–50). In another US-population case control study, 
the risk of gastric adenocarcinoma was higher in subjects reporting 2 or more family members 
with gastric adenocarcinoma (OR 5 to 12.1, 95% CI 1.35–108.5). Two additional studies have 
suggested that the risk is higher and the age of onset lower in those with a family history of 
early-onset (<50 years) gastric adenocarcinoma (51,52). In addition, a retrospective cohort 
study on US Veterans with GIM indicated that a family history of gastric adenocarcinoma was 
associated with a hazard ratio (HR) of 3.8 (95% CI 1.5-9.7) for gastric adenocarcinoma 
development (53). In keeping with this evidence, monozygotic and dizygotic twins of 
individuals with gastric adenocarcinoma have 9.9 and 6.6-fold higher risk of gastric 
adenocarcinoma respectively, compared to twins of subjects without gastric adenocarcinoma 
(54). It is important to consider that familial aggregation occurs in approximately 10% of cases, 
which in low incidence countries of gastric adenocarcinoma likely relates to heritable 
pathogenic mutations. However, truly hereditary cases are deemed to account for 
approximately 1-3% of all gastric adenocarcinoma cases and include three main subgroups: 
hereditary diffuse gastric cancer (HDGC), familial intestinal gastric cancer (FIGC) and other 
single-gene syndromes associated with a possible increased risk of gastric adenocarcinoma 
(55). The latter include gastric adenocarcinoma and proximal polyposis of the stomach 
(GAPPS)(56,57), Li-Fraumeni syndrome, familial adenomatous polyposis (FAP), Peutz-
Jeghers syndrome, juvenile polyposis, Cowden’s syndrome/PTHS, and Lynch syndrome(58). 
More than 90% of individuals with a PTEN pathogenic variant who underwent at least one 
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upper or lower endoscopy were found to have polyps(59). Histologic findings varied, ranging 
from ganglioneuromatous polyps, hamartomatous polyps, and juvenile polyps to adenomatous 
polyps. The association of gastric cancer with familial adenomatous polyposis (FAP) is mainly 
based on case reports and thus remains weak. 
 
Although this guideline does not cover management of hereditary gastric cancer it is important 
to know how to take an appropriate family history, in order to suspect familial gastric cancer 
and know when to refer for genetic counselling. Outside the context of specialised genetic 
counselling clinic, where the three-generation comprehensive pedigree is recommended, in 
standard clinical practice it is recognised that it is sufficient to focus on first-degree (parents, 
children and siblings) and second degree relatives (grandparents, aunts/uncles, 
nieces/nephews, grandchildren and half-siblings) in order to assess the empiric individual risk 
profile (60). Affected relatives should be from the same lineage (Maternal or paternal) and be 
first degree relatives of each other. The age of diagnosis, the histological type of gastric cancer 
(if possible) and the occurrence of GI polyps and other cancers, including colorectal, ovarian, 
breast and pancreatic cancer should be recorded. Criteria for referring to genetic services are 
outlined in Table 4 (61,62). It is important to note that the criteria for a clinical diagnosis of 
HDGC have been slightly relaxed in the more recent updated clinical guidelines and that a 
history of breast cancer is particularly important for a clinical suspicion of familial gastric 
cancer important as there is clustering between gastric and breast cancers, not only in HDGC 
(Lobular type) but also in other familial cancer syndromes, including Peutz-Jeghers and 
Cowden(61,63). Individuals that fulfil the family history criteria for suspected familial gastric 
cancer in the absence of a mutation identified could be considered for endoscopic surveillance. 
Ideally this should be offered as part of a clinical trial as there are no validated surveillance 
protocols in this group of individuals. In the absence of evidence we would suggest 3 yearly 
endoscopy with high-definition endoscopy and image enhancement as a possible protocol. 
Details of genetic centres in the UK can be found on the British Society of Genetic Medicine 
website https://www.bsgm.org.uk.  
 
 
 
Table 4:Criteria for referring to genetic services 
Suspected familial gastric cancer 
1. Gastric cancer in one family member before age 40, or 
2. Gastric cancer in two 1st / 2nd  degree relatives with one diagnosis before age 50*, or 
3. Gastric cancer in three 1st / 2nd  degree relatives independent of age*, or 
Suspected Hereditary Diffuse Gastric Cancer 
1. One case of diffuse gastric cancer before age 40, or  
2. Two cases of gastric cancer regardless of age in two 1st / 2nd  degree relatives, at least one 
confirmed diffuse gastric cancer*, or 
3. Personal and family history of diffuse gastric and lobular breast cancers, with one diagnosis 
before age 50 
4. A personal or family history of cleft lip/palate in a patient with diffuse gastric cancer 
5. In situ signet ring cells or pagetoid spread on gastric biopsies 
* in order to account for significant family history, the affected relatives need to be within the same side of the 
family (maternal or paternal) 
 
 
There are multiple genetic polymorphisms that have been shown to be associated with an 
increased risk of gastric cancer, in particular related to inflammatory response genes such as 
interleukins, interleukin receptors, and tumour necrosis factor (64). There currently is 
insufficient evidence to recommend routine DNA genotyping to inform clinical decisions 
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outside cases that meet the criteria for familial gastric cancer (55). A detailed discussion on 
this topic is beyond the scope of this guideline. 
 
Pernicious anaemia is another strong risk factor for gastric adenocarcinoma development. A 
systematic review by Vannella and co-workers found that the pooled incidence of gastric 
adenocarcinoma in patients with pernicious anaemia is 0.27% per year with a relative risk (RR) 
of 6.8 (95% CI 2.6-18.1) (65). A more recent population-based case-control study on 1,138,390 
cancer cases compared with 100,000 matched controls found that in patients with pernicious 
anaemia the ORs for gastric adenocarcinoma and gastric NETs were 2.18 (95%CI 1.94-2.45) 
and 11.4 (95% CI 8.9-14.7), respectively (66). Since these were unverified pernicious anaemia 
cases, this was likely a marked underestimate of the cancer risk in true pernicious anaemia 
patients. Substantiating a diagnosis of pernicious anaemia however can be challenging. 
Megaloblastic anaemia and vitamin B12 deficiency can depend on a multitude of clinical 
conditions and the diagnostic accuracy of auto-antibodies is low (low specificity for anti-
parietal cell antibodies and low sensitivity for anti-intrinsic factor antibodies) (67,68). 
Therefore, in order to stratify cancer risk, it is essential that histopathological evidence of auto-
immune atrophic gastritis corroborates the serological diagnosis.  
 
It has long been suggested that a previous history of gastric surgery for benign disease is a risk 
factor for gastric adenocarcinoma.  Three early retrospective cohort studies have shown an 
increased gastric adenocarcinoma risk in individuals carrying a gastric stump from  previous 
surgery for non-malignant disease compared to the general population (69–71), while one case-
control study did not reach similar conclusions (72). The discrepancy may be resolved by a 
more recent and large retrospective study which found that the risk of gastric adenocarcinoma 
in a gastric stump only increases after 30 years from gastric surgery with an SIR of 2.29 (95% 
CI 1.38-3.57) (73). Hence, it is reasonable to conclude that the risk of gastric adenocarcinoma 
arising in the gastric stump is unlikely to be significantly increased within the first 15 years 
post-surgery. However, it should be noted that these data may be confounded by H. pylori 
status. 
 
Ethnicity is strongly related to the risk of gastric adenocarcinoma. Several retrospective cohort 
studies conducted in US and UK populations showed that Whites appear to have a lower risk 
compared to Asians (2.1 fold higher incidence), Blacks (1.7 fold higher incidence) and 
Hispanic-Latinos (1.7 fold higher incidence) (74–78). Among Asians, Chinese and Koreans 
appear to have the highest risk of a pre-malignant stomach with an OR of 4.77 (95% CI 4.54–
5.01) and 7.39 (95% CI 7.06–7.73), respectively (21). These differences are likely to be, at 
least in part, explained by differences in H. pylori prevalence, H. pylori subtypes, and host 
genotypes. 
 
There is evidence that older age is a risk factor for developing gastric adenocarcinoma 
reflecting the duration of H. pylori gastritis. Different studies report different age groups to 
study this association, e.g. 45, 50 or 75 years of age, hence it is difficult to identify an age cut-
off to guide clinical decisions (25,79,80). However, three studies have shown that age more 
than 45 years is associated with a significant OR between 1.92 and 3.1 for progression of 
premalignant stomach to gastric adenocarcinoma (25,81,82). Hence, it is reasonable to consider 
for potential screening strategies 45 years of age as a useful threshold. 
 
Males appear to be at increased risk of gastric adenocarcinoma compared to females. Two 
cohort and one case control studies showed different strengths of this association with a relative 
incidence in male compared to female ranging from 1.3 to 3 fold higher (74,79). This does not 
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apply to cases of gastric adenocarcinoma occurring before the age of 40 years, likely due to the 
domineering genetic background responsible for early-onset cancer (55,83). 
 
Smoking seems to be an additional risk factor for gastric adenocarcinoma development, 
particularly, but not limited to, gastric cardia adenocarcinoma. Smoking appears to be 
responsible for 18% of gastric adenocarcinoma risk (84) and this relates to an increase in the 
risk by 1.45-2 fold according to different studies (85,86). However, a recent meta-analysis only 
showed a trend for increased risk of gastric adenocarcinoma development in current smokers 
which did not meet statistical significance (OR 1.49; 95% CI 0.99-2.225) (87). 
  
Other risk factors that have been studied and were assessed by the working group include 
alcohol consumption, diabetes, obesity, and PPI use (88–90). For these factors the available 
evidence is conflicting or does not show a clear relation to the risk of gastric adenocarcinoma 
development. In particular for obesity there is sufficient evidence to conclude that this is 
associated to the risk of cardia cancer, but not non-cardia gastric cancer (91). There have 
been a number of recent studies investigating the association of PPIs, and gastric cancer. A 
study by Cheung et al assessing patients who were treated for Helicobacter pylori, 
demonstrated an association between PPI use and gastric cancer in a population from Hong 
Kong. PPI use was associated with a 2.44 fold increase in cancer. No increase was detected in 
H2 antagonists and most cancers were non-cardia. There were significant flaws in this study. 
Most importantly the PPI group were 10 years older on average than the non-PPI group and 
as gastric cancer increases with age it would expected that the risk would be greater in this 
group. Similarly a Swedish study showed a similar increase in gastric cancer in PPI users 
with the greatest risk in younger men. No difference was however found in a US study 
looking at pantoprazole. It can be concluded that although there is an association between PPI 
use and gastric cancer, no causal link has been proven. Furthermore, this association may be 
limited to specific populations and limited to patients who have had H. pylori eradication 
(92–94). We make reference to a BSG position statement (95) which recommends that if acid 
suppression is required after H.pylori eradication, H2-antagonists should be used first and if 
these are ineffective PPIs can be initiated with the above information being shared with the 
patient. In other patients there is no evidence at the moment to advise against the use of PPIs 
first line for short term use. Prolonged use should be accompanied with an explanation of the 
evidence for possible risks as described above.  
 
 
 
6.1.3 H. pylori and gastric cancer 
 
Who should be tested and treated for H. pylori to reduce the risk of gastric cancer?  
 
We do not recommend testing and treating for H. pylori to reduce the incidence of gastric 
cancer in low incidence areas such as the UK (Evidence level: high quality; Grade of 
recommendation: high; Level of agreement: 100%) 
 
Several studies in rodents support the hypothesis that eradication of H. pylori infection prevents 
the subsequent development of gastric adenocarcinoma (96,97). However, the benefits were 
reduced in these animal models when infection was eradicated at later stages in the natural 
history of the disease. Multiple human cohort studies as well as randomised clinical trials have 
now been performed to assess whether testing for H. pylori in the asymptomatic population 
and its subsequent eradication in infected subjects reduces the subsequent incidence of gastric 
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cancer. In turn, these studies have been subjected to systematic reviews and meta-analyses by 
at least three independent research groups. The conclusions were that searching for and 
eradicating H. pylori reduced the incidence of gastric adenocarcinoma in healthy asymptomatic 
infected individuals, with the number of patients needed to treat was as low as 15 for Chinese 
men, but as high as 245 for US women (98,99) (100). The benefits of eradication varied with 
baseline gastric cancer incidence, but did not differ with study design, sex, or follow-up period 
baseline risk (101). 
 
Thus, there is compelling evidence that H. pylori eradication is effective at reducing the 
subsequent risk of gastric adenocarcinoma development. In areas of low to moderate gastric 
adenocarcinoma incidence such as the UK however, it has been suggested that this is not a 
cost-effective strategy. However, as recently argued by O’Connor et al (102), there may be 
additional benefits associated with H. pylori eradication such as a reduction in peptic ulcer 
disease and dyspepsia and these have not been considered in all the proposed economic models. 
Other potential consequences of widespread H. pylori eradication therapy should also be 
considered when considering the risk benefit ratio of such a strategy. These include the 
potential emergence of antibiotic resistant strains of the organism and treatment-associated side 
effects some of which, although rare, can be serious, such as Clostridium difficile infection 
(102). 
 
Therefore, although H. pylori eradication is a feasible, efficacious, and potentially cost-
effective method (at least in some populations) for reducing the risk of subsequent gastric 
adenocarcinoma development, its use has not yet been adopted anywhere in the world. The 
final results of a very large Chinese trial involving more than 180,000 participants will be 
available within the next few years and its results may influence future public health policy in 
this area, particularly in East Asian countries (103). However, at present, in areas of relatively 
low gastric cancer incidence such as the UK, we cannot currently recommend population 
testing and treating for H. pylori as a means for preventing subsequent gastric cancer 
development  
 
Does eradication of H. pylori prevent progression to cancer? 
 
We recommend H. pylori eradication to reduce the risk of gastric adenocarcinoma 
development in patients who have H. pylori-associated gastric atrophy (Evidence level: 
High quality; Grade of recommendation: high; Level of agreement: 100%) 
 
We suggest that H. pylori eradication may be of some benefit to reduce the risk of 
developing gastric adenocarcinoma in those who already have H.pylori-associated 
gastric intestinal metaplasia, dysplasia, or cancer. (Evidence level: High quality; Grade of 
recommendation: weak; Level of agreement: 100%) 
 
Although there is good evidence that H. pylori eradication reduces the subsequent risk of 
gastric adenocarcinoma development, it has been hypothesised that there may be a "point of 
no return" in the precancerous cascade. This question has been assessed in multiple studies and 
has been the topic of two recent independent systematic reviews and meta-analyses and most 
recently a large randomised controlled trial. 
 
Chen et al performed a meta-analysis of ten studies from eight randomised controlled trials 
with a total of 7,955 participants (104). These authors divided participants into subgroups based 
on their baseline diagnoses comparing a group without GIM (normal, non-atrophic gastritis, 
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GA) and a group with GIM (GIM, or dysplasia). H. pylori treatment compared with controls 
significantly reduced the risk of gastric cancer, with a pooled RR of 0.64 (95% CI, 0.48-0.85). 
Subgroup analysis for patients with non-atrophic gastritis and GA yielded similar results (RR 
= 0.25, 95% CI, 0.08-0.81). However, this difference was not observed in patients with GIM 
or dysplasia (RR = 0.88; 95% CI, 0.59-1.31). The authors concluded that H. pylori treatment 
no longer decreased the risk of gastric adenocarcinoma development once patients had 
developed GIM or dysplasia,. 
 
Rokkas et al., 2017 recently published a second independent meta-analysis on this topic (105). 
They analysed 26 studies (10 randomised controlled trials and 16 cohort studies) and included 
52,363 subjects. The risk of gastric adenocarcinoma among patients in whom H. pylori had 
been successfully eradicated was significantly lower than that among controls (pooled RRs 
[95% CI] 0.56 [0.48-0.66], Z= -7.27, P=0.00001). In patients with precancerous lesions 
however, subgroup analyses showed that patients with non-atrophic or GA benefitted from H. 
pylori eradication to decrease the risk of gastric cancer development, whereas those with GIM 
or dysplasia did not. In contrast to these data, a recent large randomised placebo-controlled 
trial which demonstrated a significant reduction in metachronous gastric adenocarcinoma rates 
after endoscopic resection of intramucosal cancer and HGD in the H pylori eradication group 
(13.4 % vs 7.9%; P=0.03) (106). Furthermore, there appeared to be a reversal in the severity 
of both GA and GIM in the corpus, but not in the antrum. 
 
Current high-quality data therefore suggest that while eradication of H. pylori reduces 
subsequent gastric adenocarcinoma risk in patients who have non-atrophic or GA, these 
benefits are not consistently maintained in patients who have developed GIM, dysplasia or 
cancer. The published meta-analyses did not however address whether the histological type, 
severity, or location of GIM or dysplasia influence this response to treatment. Although early 
data do not consistently support the use of H. pylori eradication in patients who already have 
established intestinal metaplasia, dysplasia, or cancer, the aforementioned RCT provides 
evidence to treat those with established cancer or HGD.  
 
Although most of the published evidence is from the Far East, there is no compelling evidence 
to suggest that the fundamental process of gastric carcinogenesis differs according to 
geographical location. The published evidence suggests that H. pylori eradication appears to 
prevent gastric cancer development in some patients who have atrophic gastritis. Despite the 
lack of studies from the UK and Europe, H. pylori eradication is likely to benefit some 
European patients who have atrophic gastritis and has a very low risk of causing serious adverse 
events. Further studies in European populations are however needed to expand the pool of 
evidence that will influence this recommendation when these guidelines are revised. 
 
The success of a H. pylori eradication strategy in order to try to prevent cancer development in 
patients who have premalignant gastric conditions will obviously be influenced by the success 
rate of the actual bacterial eradication regime that is used. The choice of eradication regime is 
beyond the scope of these guidelines, but its efficacy should be monitored. Regimes other than 
classical triple therapy may need to be employed, particularly in geographical locations where 
the rates of H. pylori antibiotic resistance are known to be high. 
 
In addition to the conventional Correa cascade of gastric carcinogenesis there are other gastric 
conditions that are potentially associated with an increased risk of gastric cancer development, 
in particular some gastric polyps (107). Although there is good evidence to suggest that H. 
pylori eradication leads to the regression of gastric hyperplastic polyps, no studies appear to 
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have analysed whether this influences subsequent gastric adenocarcinoma risk (108–110). 
Studies on the effects of H. pylori eradication in patients with gastric adenomas are too small 
to draw any valid conclusions (111). 
 
 
6.1.4 Biomarkers and gastric cancer 
 
What biomarkers are useful in the management of these lesions?  
Can they be applied to population screening, monitoring those at risk, or those with known 
lesions? 
 
Measurement of serum pepsinogen I and serum pepsinogen I/II ratio alone or in 
combination with H. pylori serology, and/or Gastrin -17 can identify individuals with 
extensive atrophic gastritis. (Evidence level: Low quality; Grade of recommendation: weak; 
Level of agreement: 93%) 
 
We do not recommend the use of biomarkers as a screening tool in areas with a low 
incidence of gastric adenocarcinoma, such as the UK. (Evidence level: Low quality; Grade 
of recommendation: weak; Level of agreement: 100%) 
 
 
Chronic atrophic gastritis (CAG), dysplasia and gastric adenocarcinoma 
 
Pepsinogen I (PGI) is mainly secreted by chief and mucous neck cells in the fundic mucosa 
whilst pepsinogen II (PGII) is also secreted by pyloric and duodenal Brunner’s glands. 
Approximately 1% of pepsinogens are found in the serum with their serum level accepted as a 
marker for the morphological and functional status of the gastric mucosa (10,112,113). Serum 
PGI and PGII levels both increase in gastric mucosal inflammation; however, as GA develops 
and specialised cells are lost, PGI and PGII levels decrease, usually more marked in PGI, 
resulting in low serum PGI and a low PGI/II ratio (114). 
 
The combined use of serum PGI and PGI/II ratio measurements are an accepted useful 
biomarker for pre and malignant gastric lesions (112). Studies exploring their use as a 
population screening tool, where those with a positive pepsinogen result progress to endoscopic 
examination, have been demonstrated to be acceptable in screening asymptomatic populations 
with a good uptake of invitations for endoscopy, over 60%, in those with a positive pepsinogen 
result (115,116).  
 
Biomarker detection of CAG, dysplasia and gastric cancer 
There are numerous studies across many different countries and populations that have explored 
the use of serum pepsinogen testing for detection of CAG, dysplasia, and gastric 
adenocarcinoma. The majority of these studies are from countries with a higher incidence of 
these lesions than the UK. With regards to countries with an incidence of gastric 
adenocarcinoma similar to the UK, a study by Broutet et al in 2003 assessed serum pepsinogen 
testing across 14 European nations and determined that PGI/II ratio may be of use as a 
screening test (112,117,118). However, in the majority of studies the values used to define a 
positive pepsinogen test result and the study outcomes are reflective of populations that 
ultimately differ from the UK population. Additionally, many of these studies use differing 
cut-off values that make comparison difficult. However, the most frequently used values for 
these studies is a PGI <70 ng/ml and a PGI/II ratio ≤ 3 (112). Values can be affected by 
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laboratory methodologies and population settings and therefore may require adjustment if they 
were to be applied to the UK population.  
 
A recent meta-analysis by Huang et al found that serum pepsinogen testing had a sensitivity 
and specificity of 69% and 73% for gastric cancer diagnosis and 69% and 88% for CAG 
diagnosis, respectively (112). This analysis included a study population of over 30,000 
individuals, across 13 different countries and diagnosis confirmed with gastroscopy and 
biopsy. This is comparable to the 2004 meta-analysis performed by Dinis-Ribeiro et al, using 
a cut-off of PGI <50 and PGI/II ratio ≤ 3 for dysplasia detection, where sensitivity and 
specificity was 65% and 74-85% respectively (117). This included a study population of 
approximately 300,000 patients. Finally, in a 2014 meta-analysis by Terasawa et al a study 
population of approximately 32,000 patients where individuals were prospectively followed up 
between 3.9-14 years, found that a positive pepsinogen test had a sensitivity of 57% and 
specificity of 76% for the development of gastric adenocarcinoma (119). 
 
Biomarker population screening 
Whilst pepsinogen testing has been demonstrated as a useful tool for population screening in 
high-risk areas, its use in low-risk areas such as the UK has not been explored (116,119,120). 
In particular one must address whether the moderately effective sensitivities and specificities 
of pepsinogen testing are cost-effective for screening an asymptomatic population where the 
incidence of the disease is low. A 2015 study by Yeh et al utilised a mathematical simulation 
model to calculate the cost effectiveness of population screening strategies based on biomarker 
and endoscopic technologies in the low-risk USA population (Defined as an age-standardised 
rate, ASR <10 per 100,000). This study found that although one time serum pepsinogen testing 
at the age of 50 could prevent one in four gastric adenocarcinoma among men it was not of 
high value in improving cancer outcomes. However, targeting the high-risk group of male 
smokers over 50 years old could be a cost-effective way to reduce mortality of gastric 
adenocarcinoma (113). This screening model requires further exploration. 
 
H. pylori serology has been studied extensively both as a population screening tool alone, as 
part of a “test and treat” strategy, and in conjunction with pepsinogen testing. Whilst its use 
as a screening tool or in the “test and treat” strategy may have advantages in high-incidence 
areas (defined as an age-standardised rate, ASR >20 per 100,000), the disadvantages 
including low specificity and antibiotic resistance in low-risk populations render its use 
redundant (121). The use of H. pylori serology in combination with pepsinogen is more 
accurate. In particular the finding of negative serum anti-H. pylori (Hp) IgG antibody and 
positive pepsinogen measurements suggests extensive GA and thus these individuals are at 
highest risk of progression to cancer (10,121). The ABCD method for the detection of high 
gastric adenocarcinoma risk individuals has been extensively investigated in high-risk 
populations. This method categorises patients tested for H. pylori serology (HP) and the 
ratios of serum PGI and PGII (sPG) into low risk (A: HP -, sPG-), moderate risk (B: HP+ and 
sPG-), and high risk (C: HP+ and sPG+; D: HP-, sPG+). Although in a 20 year prospective 
study the hazard ratios for developing gastric adenocarcinoma were 15 for group D when 
compared to group A (122), further evidence is required to support the use of these 
approaches in a low risk population. 
 
Gastropanel® combines PGI, PGII, gastrin-17 and H. pylori serology. A recent meta-analysis 
assessed the performance of this serum panel test for the diagnosis of CAG in 4241 subjects. 
The sensitivity for CAG was 74.7% (95% confidence interval (CI), 62.0-84.3) and the 
specificity was 95.6% (95%CI, 92.6-97.4). With a prevalence of CAG of 27% (median 
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prevalence across the studies), the negative predictive value was 91% and positive predictive 
value was 86% (123). Thus, although studies to date have shown promise, there is little in the 
way of evidence to support its use with conflicting data on its efficacy (124–126). 
 
Finally, note is made of studies exploring the detection of volatile organic compounds in 
exhaled breath that are associated with the detection of gastric adenocarcinoma (127).  
 
6.2 Endoscopic diagnosis of pre or early malignant lesions of the stomach 
 
6.2.1 Ensuring high quality endoscopic evaluation 
 
Outside the recommendations within the UK guidelines for quality endoscopy are there further 
processes that are suggested for the detection and diagnosis of pre or early malignant lesions 
of the stomach? Is a station-based approach beneficial? 
 
We recommend patients at higher risk for gastric adenocarcinoma, including gastric 
atrophy and gastric intestinal metaplasia should undergo a full systematic endoscopy 
protocol of the stomach with clear photo documentation of gastric regions and pathology. 
We suggest a minimum examination time of 7 minutes. (Evidence level: moderate quality; 
Grade of recommendation: strong; Level of agreement: 100 %) 
 
An endoscopy needs to be of high quality in order to detect dysplasia and early cancers, 
particularly in light of post-endoscopy gastric cancer rates of 11.3% (128). Recognising and 
targeting high-risk patients with GA and GIM may be the most effective means to improve 
gastric cancer detection, and possibly survival, in the UK. There are three basic principles, 
which are part of routine practice: cleaning of the gastric mucosa, adequate distention of the 
gastric wall by air insufflation, and mapping the entire stomach.  
 
Although there is little available evidence on the use of smooth muscle relaxants and mucosal 
cleaning techniques, the new BSG Position Statement on Quality Standards in Upper 
Gastrointestinal Endoscopy recommends: ‘Adequate mucosal visualisation should be achieved 
by a combination of adequate air insufflation, aspiration and the use of mucosal cleansing 
techniques’ (129). We recommend this guidance is also applied to inspection of GA and GIM. 
 
There is also a paucity of data on the assessment of a complete endoscopic procedure. In 
particular there are no clinical trials to directly clarify key performance indicators (KPI) or 
quality assurance (QA) for improving gastric cancer detection, or studies exploring the 
outcomes of systematic screening protocols for the stomach. The ESGE performance measures 
for upper GI endoscopy have suggested the inspection of the oesophagus, stomach and 
duodenum should last at least 7 minutes from intubation to extubation (130). This statement 
was based on a retrospective cohort study by Teh et al which aimed to determine the diagnostic 
yield for early neoplastic lesions in the stomach (131). After evaluating 837 endoscopies of 
symptomatic patients with no history of gastric cancer, they found that a ‘slow’ endoscopist (> 
7 minute examination) was twice as likely to detect high risk gastric lesions, defined as biopsy 
evidence of GA, GIM, gastric dysplasia, or cancer and three times as likely to detect a case of 
dysplasia or cancer compared to a ‘fast’ endoscopist (< 7 minute examination) (131,132).  
 
Photo-documentation might be an indirect quality indicator. Endoscopists with longer 
procedure times, who take more than 4 pictures, detect more pathology (132). The ESGE has 
recommended 5 areas in the stomach should be photo-documented including the cardia and 
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fundus in inversion, corpus in forward view including lesser curvature, corpus in retroflex view 
including greater curvature, angulus in partial inversion, and antrum. Images may be utilised 
in case discussions, patient management and compared to histology to aid learning. 
 
In Japan, a systematic screening protocol for the upper GI tract has been developed, although 
this is considered too complex for routine clinical practice (133). This was revised by the 
Japanese Society of Gastroenterological Cancer Screening (JSGCS) to a simplified, but still 
elaborate protocol (134). Yao has more recently simplified this further to propose as a 
minimum required quality standard a “systematic screening protocol for the stomach (SSS)” 
(135). This is a station-based approach whereby each area of the stomach is viewed and 
photographed in either a clockwise or counter-clockwise manner. The 22 pictures are arranged 
according to the order of the procedure. Additional pictures are taken of lesions (Figure 2). A 
recent study form China found that training including a systematic inspection protocol with 20 
photos increased the detection of early gastric cancer from 0.2 to 2.3 % (136) 
 
An e-learning module has been developed to teach endoscopists how to diagnose early gastric 
cancer based on the characterisation of Gastritis-like lesions, Ulcerative lesions, and Polypoid 
lesions, the so-called GUP system (137,138). The GUP system has been evaluated in a 
randomised controlled trial involving 332 endoscopists in 27 countries with higher mean 
improvement rate in the e-learning group than that of the non e-learning group (138). A further 
study clearly demonstrated the efficacy of an e-learning system in improving endoscopists’ 
capabilities to diagnose early gastric cancer using Magnification-Narrow Band Imaging (M-
NBI) (139). Such validated training modules may be incorporated into any future quality 
improvement programs aimed at improving gastric cancer diagnosis. 
 
We recommend that when either GA or GIM are recognised on WLE, a full systematic 
endoscopic examination of the whole stomach is performed, taking no less than 7 minutes, with 
full photo-documentation of antrum, pylorus, incisura, lesser curve, greater curve, fundus, and 
cardia. For patients without known risk factors for gastric cancer, we recommend a 
standardised high-quality endoscopy as defined in the UK Quality in Upper Gastrointestinal 
position statement. 
 
 
6.2.2 Optical endoscopic diagnosis of the pre or early malignant stomach  
 
How does one identify pre or early malignant lesions and ensure accurate documentation when 
reporting? Are there mucosal features that identify these lesions (including recognizing the 
atrophic border)? 
 
What histopathogical and imaging modalities are suggested for the staging of glandular pre- 
and early gastric malignant lesions of the stomach? 
 
 
Gastric atrophy and gastric intestinal metaplasia may be detectable by white light 
endoscopy, however the accuracy is poor. Therefore, we do not recommend establishing 
a diagnosis or risk-stratification using white light endoscopy alone. (Evidence level: 
moderate quality; Grade of recommendation: strong; Level of agreement: 93%) 
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We recommend image-enhanced endoscopy is the best imaging modality to accurately 
detect and risk-stratify gastric atrophy and gastric intestinal metaplasia  (Evidence level: 
moderate quality; Grade of recommendation: strong; Level of agreement: 100%) 
 
We recommend that endoscopic appearances on white light endoscopy suggestive of 
atrophy or gastric intestinal metaplasia require escalation to high resolution, image-
enhanced endoscopy and, where available, magnification endoscopy (Evidence level: low 
quality; Grade of recommendation: strong; Level of agreement: 100%) 
 
We recommend that the location and extent of gastric atrophy and gastric intestinal 
metaplasia should be clearly documented with photo-evidence. Endoscopic grading 
should be documented as distal gastric (affecting antrum or incisura - low risk) or 
proximal gastric (affecting the corpus with or without the antrum and incisura - high 
risk). (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 
93%) 
 
We recommend that endoscopic appearances on white light endoscopy of gastric 
dysplasia and early gastric cancer (differences in colour, loss of vascularity, slight 
elevation or depression, nodularity, thickening, and abnormal convergence or flattening 
of folds) require escalation to image-enhanced endoscopy and, where available, 
magnification endoscopy (Evidence level: low quality; Grade of recommendation: strong; 
Level of agreement: 100%) 
 
We recommend image-enhanced endoscopy is the best imaging modality to accurately 
diagnose and stage gastric dysplasia and early gastric cancer (Evidence level: moderate 
quality; Grade of recommendation: strong; Level of agreement: 100%) 
 
 
Endoscopic detection and staging of GA, GIM and dysplasia is achievable with high resolution 
WLE but improved with image enhancement and magnification endoscopy. The white light, 
image enhanced and magnification appearances of the different mucosal patterns within the 
stomach are described below, covering the normal antrum and corpus as well as GA and GIM. 
 
Normal gastric appearances 
 
White light endoscopy 
 
Typically, the surface of the normal corpus, when the stomach is empty and not distended, is 
almost invariably in folds, also called rugae, which vary in size depending upon the degree of 
insufflation during the endoscopic assessment. In contrast, the surface of the normal fundus 
and antrum are smooth. The colour of the normal gastric mucosa, as indeed of the whole 
gastrointestinal tract, is velvety glossy dark rose or red with a regular arrangement of the 
collecting venules (CV) usually visible as red spidery vessels in the normal corpus (140–143). 
The presence of these collecting venules is characteristic of a normal stomach without H. pylori 
(sensitivity 93%, specificity 48%) (140,144,145). With current white light, high resolution 
endoscopes the round ‘pit patterns’ of the corpus and elongated ‘pit patterns’ of the antrum can 
be seen without magnification or enhancement (Fig 3 Ai & 1Di).  
 
Magnification and enhanced endoscopy 
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The two key features that characterise the gastric mucosa on magnifying endoscopy include 
the surface structure and vascular architecture.  
 
Essentially, the corpus mucosa has straight or tubular glands with round ‘crypt openings’ 
(CO)(146). These dark round pits are surrounded by the lighter coloured marginal crypt 
epithelia (MCE), then the darker circular sub-epithelial capillary network (SECN).  This 
structure forms the typical foveolar type pattern, where dark areas (capillaries) surround light 
areas (glands) (147–149).  These appearances correspond with the tubular gland structure of 
the corpus mucosa histologically (Fig 3 Ei, Eii & F). In NBI, the pattern "regular vessels with 
circular mucosa” is associated with normal histology (accuracy 83%; 95% CI 75%-90%) (150).  
 
In contrast to the corpus, the glands in the antrum are oblique and branching and the dark ‘pit 
openings’ are grooved. The light coloured ridged or villiform epithelium (MCE) surrounds the 
dark SECN, which can be seen as coiled vessels (Fig 3 Aii & Aiii). This appearance is termed 
the ‘groove type pattern’ (147,148). These appearances correspond with the papillary surface 
structure of the antral mucosa histologically (Fig 3 Bi, Bii & C). 
 
Chronic H. pylori-gastritis 
 
There are a number of endoscopic features suggestive of chronic H. pylori gastritis including 
the absence of collecting venules, antral nodularity, enlarged gastric folds, enlargement and 
destruction of the gastric glands, sticky tenacious adherent mucous, turbid gastric juice, and 
xanthomas (140–142). Loss of collecting venules and capillary vascular structure was 
correlated with chronic inflammation and activity. With progression of mucosal atrophy 
irregular collecting venules become visible (151). 
 
Gastric atrophy 
 
There are four principal endoscopic features of GA described by Nakayama, Uedo and Yao  
(152–154): pallor, loss of gastric folds, prominence of the vessels, and the atrophic border (Fig 
4). Increased visibility of the vascular network showed a sensitivity of 48% and specificity of 
87%, while the loss of gastric folds has a sensitivity 67% and specificity of 85% (155). 
 
Long-term cohort studies suggest the Kimura-Takemoto classification is a useful risk 
stratification assessment tool to predict gastric adenocarcinoma development (26,31,156). 
Essentially this tool utilises the extent of the atrophic border (the border between the pale 
atrophy and normal red coloured stomach), to stage the extent of GA (Fig 4). In a cross 
sectional cluster sampling historical study between the UK and Japan, endoscopic grading was 
shown to be comparable to histopathology and correctly predict histopathological atrophy with 
few false negatives (157,158). This work needs further confirmation in a larger setting outside 
of Japan. The Kimura-Takemoto classification has been simplified to a modified staging 
system involving antrum only (antral), antrum to incisura (antral dominant), antrum to lesser 
curve (corpus dominant), and antrum, lesser curve and greater curve (Pan-atrophy). This 
staging system integrates the Sydney biopsy system discussed later (Fig 5). The GDG agreed 
that the extent of GA and GIM should be stratified as low risk (Involving the antrum and 
incisura) or high risk (Involving the corpus and antrum/incisura or corpus alone). 
 
Gastric intestinal metaplasia 
 
White light endoscopy 
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GIM typically appears as small grey-white slightly elevated plaques surrounded by mixed 
patchy pink and pale areas of mucosa causing an irregular uneven surface (Fig 6A). Mottled 
patchy erythema has also been positively associated with GIM (159). However, diagnosis using 
standard endoscopy alone (without high resolution or enhanced imaging) is unreliable (160–
165) .  
 
Magnification & image enhanced endoscopy 
 
As patches of GIM expand, the straight/tubular glands of the corpus elongate to a ‘groove type 
pattern’ similar to that of the antrum or villiform pattern of the intestine (Fig 6C & D). Although 
these changes can easily be distinguished from the normal mucosal background in the corpus 
both with high resolution white light and enhanced endoscopy, GIM in the antrum is more 
difficult to characterise as the pre-existent mucosal architecture is quite similar and appears 
oblique and grooved as well (148,166). Additional features of GIM include the light blue crest 
(LBC) and the marginal turbid band (MTB) (167) and the white opaque substance (lipid 
droplets) obscuring the sub-epithelial capillaries(168). The LBC is a fine, blue-white line on 
the crest of the mucosal surface seen with NBI enhancement and is a highly specific sign of 
the presence of GIM (166,169) (Fig 6E&F). The MTB is a white turbid band on the mucosal 
surface. It is suggested that the MTB may represent a sign of early GIM, whereas the LBC 
appears with progression to severe GIM, although whether this is reproducible remains 
uncertain. 
 
6.2.3 Optimal techniques for the detection and classification of gastric atrophy and gastric 
intestinal metaplasia 
 
Most studies have demonstrated improved accuracy of enhanced and magnification imaging in 
the classification and detection of GA, GIM, dysplasia and cancer, when compared to WLE 
(150,162,163,165,170,171). An overview of enhanced imaging studies with various modalities 
and their performance characteristics is provided in Table 5.  
 
TABLE 5 Endoscopic imaging modalities and performance characteristics for the 
diagnosis for gastric atrophy and intestinal metaplasia 
 
Author (year) Location No of 
patients 
Study design Modality Sensitivity (%) Specificity (%) Condition 
Dinis-Ribeiro 
2003(155,172) 
Portugal 136 Prospective ME MB 76.4 86.6 GIM 
Redeen 
2003(155) 
Sweden 488 Prospective WLE 67-90 (absence 
of folds) 
48-80 (body 
visible vessels) 
14 (antrum 
visible vessels) 
85-84 (absence of 
folds) 
87-87 (body visible 
vessels) 
91 (antrum visible 
vessels) 
AG 
Uedo 2006(166) Japan 107 Prospective NBI ME 89 93 GIM 
Anagnostopoulos 
2007(149) 
UK 95 Prospective WLE ME 90 (body type 4 
pattern) 
96 (body type 4 
pattern) 
AG 
Bansal 2008(147) USA 47 Pilot 
feasibility 
NBI 80 
(ridge/villous 
pattern) 
100 (ridge/villous 
pattern) 
GIM 
Guo 2008(173) China 53 Prospective WLE vs 
CLE 
36.88  (WLE) 
98.13 (CLE)  
91.59  (WLE) 
95.33 (CLE)  
GIM 
Tahara 
2009(174) 
 
Japan 106 Prospective ME NBI 
(body) 
73.3 (type 3 
NBI IM) 
50 (type 3 NBI 
AG) 
66.7 (WLE 
open type) 
95.6 (type 3 NBI 
IM) 
96.3 (Type 3 NBI 
AG) 
72 (WLE open 
type) 
GIM 
and AG 
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Capelle 
2010(175) 
The 
Netherlands 
43 Prospective NBI vs 
WLE 
71 (NBI) 
51 (WLE) 
58 (NBI) 
67 (WLE) 
GIM 
Eshmuratov 
2010(170) 
 
Korea 1330 MC 
Prospective 
WLE 61.5 (antrum)-
46.8 (body) 
57.7 (antrum)-76.4 
(body) 
AG 
Kawamura 
2011(176) 
Japan 95 with 
active DU (n 
= 24), 
diffuse-type 
(n = 24) and 
intestinal-
type (n = 
47) EGC 
Observational ME NBI Types A-1 and A-2 (modified Yagi’s 
A-B classification system) 
Severe AG-IM seen in the intestinal 
type EGCs at the lesser curvature 
(accuracy figures not supplied) 
AG and 
GIM 
Rerknimitr 
2011(177) 
Thailand 
 
38 (I 
surveillance) 
26 (II 
surveillance) 
Prospective NBI 
 
78.8/91.3 (I/II 
surveillance) 
3 criteria: LBC, 
VP, and LLC 
 
82.5/89.1 (I/II 
surveillance) 
3 criteria: LBC, VP, 
and LLC 
 
GIM 
Pimentel-Nunes 
2012(150) 
Europe 
 
85 MC 
Validation 
NBI 89 (tubulo-
villous pattern) 
48 (LBC) 
90 (tubulo-villous 
pattern) 
96 (LBC) 
GIM 
Dutta 2013(178) India 200 Randomized 
prospective 
crossover 
NBI vs 
WLE 
NBI was superior to WLE 
(accuracy figures not supplied) 
AG and 
GIM 
An 2012(167) Korea 47 Prospective ME NBI 100 (MTB) 
72 (LBC) 
66 (MTB) 
96 (LBC) 
GIM 
Kanzaki 
2012(179) 
Japan 50 with 
ECG and 
CAFG 
Cross-
sectional 
study 
AFI + 
ME NBI 
Body 
lesser 
curvature, 
groove 
type vs 
foveola 
type 
Grade of AG-IM significantly higher in 
groove type 
compared with foveola type (accuracy 
figures not supplied) 
IM and 
AG 
Savarino 
2013(180) 
Italy 100 Prospective NBI ME 80 96 GIM 
Fukuta 
2013(181) 
Japan 163 MC 
Prospective  
WLE IC WLE: 94.6 
(antrum)-86.1 
(body) 
IC: 78.4 
(antrum)-86 
(body) 
WLE: 69.1 
(antrum)-65.9 
(body) 
IC: 57.9 (antrum)-
82.6 (body) 
GIM 
Lim 2013(160) Korea 1333 Prospective WLE IM: 24 
(antrum)-24.2 
(body) 
AG: 61.5 
(antrum)-46.8 
(body) 
IM: 91.9 (antrum)-
88 (body) 
AG: 57.7 (antrum)-
76.4 (body) 
GIM and 
AG 
Pittayanon 
2013(182) 
Thailand 45 Prospective ME FICE 
+ pCLE 
ME FICE: 95.6 
ME FICE + 
pCLE: 96.5 
ME FICE: 79.2 
ME FICE + pCLE: 
90.5 
GIM 
Xirouchakis 
2013(183) 
 
Greece 119 Prospective 
open 
WLE - 
USP NBI 
AG: 86 (WLE-
USP)-62 (NBI) 
GIM: 80 
(WLE-USP)-72 
(NBI) 
AG:100 (WLE-
USP)-97 (NBI) 
GIM: 100 (WLE-
USP)-93 (NBI) 
AG and 
GIM 
Nomura 
2014(184) 
Japan 275 MC 
prospective 
WLE +/- 
IC 
77 (body)-64 
(antrum) 
79 (body)-54 
(antrum) 
AG 
Panteris 
2014(161) 
 
Greece 234 Prospective 
cross-
sectional 
WLE 74.6 94 GIM 
Kikuste 
2014(163) 
Latvia 126 Cohort FICE 60 (diagnosis)-
71 (OLGIM III-
IV) 
87 (diagnosis)-87 
(OLGIM III-IV) 
GIM 
Ang 2015(164) Asia-
Pacific 
Region 
579 MC 
prospective 
randomized 
comparative 
WLE 
NBI 
59.1 (WLE)-
92.3 (NBI) 
98.6 (WLE)-94.3 
(NBI) 
GIM 
Pimentel-Nunes 
(162)2016 
Europe-
USA 
238 MC 
prospective 
WLE 
NBI 
53 (WLE)-87 
(NBI) 
 
98 (WLE)-97 (NBI) 
 
GIM 
Sha 2017(185) China 132 Cohort 
comparative 
(AA-
NBI) vs 
NBI 
33.3 (WLE) 
66.7 (NBI) 
87.9 (AA-NBI) 
28.8 (WLE) 
68.2 (NBI) 
68.2 (AA-NBI) 
GIM 
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vs WLE 
 
 
AG, atrophic gastritis; GIM, gastric intestinal metaplasia; WLE, white light endoscopy; NBI, narrow band imaging; FICE, flexible spectral 
imaging colour enhancement; OLGIM, operative link on gastric intestinal metaplasia assessment; MC, multicenter; USP, updated Sydney 
protocol; LBC, light blue crest; VP, villous pattern; LLC, large long crest; ME, magnification endoscopy; MB, methylene blue; IC, 
indigocarmine chromoendoscopy; CLE, confocal laser endomicroscopy; pCLE, probe-based confocal laser endomicroscopy; MTB, marginal 
turbid band; AA-NBI, acetic acid- narrow band imaging; EGC, early gastric cancer; CAFG, chronic atrophic fundic gastritis. 
 
A simplified classification system using NBI without magnification by Pimentel-Nunes et al 
has been shown to be accurate and reliable for the diagnosis of GIM and dysplasia (150). In 
the validation study a tubulovillous mucosal pattern was associated with GIM (accuracy 84%). 
Irregular vessels and mucosal pattern were associated with dysplasia (accuracy 95%). The light 
blue crest (LBC) finding was moderately reliable (k=0.49), but very specific (96%) for GIM. 
In a recent study by Kanemitsu et al.(168), the sensitivity and specificity of LBC for 
histologically diagnosed IM were 62.5% and 93.8%, respectively. The sensitivity and 
specificity of WOS were 50.0% and 100.0% (95%CI 85.0% – 100.0%), respectively. The 
combination of LBC and WOS improved the overall sensitivity up to 87% and 93.8%. 
 
A second prospective multicentre study compared WLE with WLE plus NBI (162). NBI 
demonstrated a high concordance with histopathological diagnosis, superior to standard WLE. 
However, it is important to note that this study assessed WLE plus NBI, rather than NBI alone, 
and although HR WLE had a good overall sensitivity of 85% for all pathology, this decreased 
to 53% for the detection of GIM. NBI vs WLE increased sensitivity for the diagnosis of 
intestinal metaplasia significantly (87% vs. 53%; P<0.001) and for the diagnosis of dysplasia 
(92% vs. 74%). This study suggests that WLE alone is therefore not sufficiently accurate for 
GIM detection. Similar comparative results have been demonstrated in a recent prospective 
blinded trial (165). 
 
The sensitivity and specificity of WLE for the histological diagnosis of GA were reported to 
be 61.5% and 57.7%, respectively, in the antrum, and 46.8% and 76.4%, respectively, in the 
body of the stomach(170).  
 
 
Compared with WLE, NBI-ME can also effectively diagnose early gastric adenocarcinoma 
(171). 
 
Thus, in summary, the GDG agreed that WLE alone was not sufficiently accurate to reliably 
diagnose GA or GIM, and enhanced optical techniques should be used for diagnosis and 
staging. 
 
A scale for endoscopic staging of GIM using NBI was created and returned an AUC of 0.98 
for WLE followed by NBI for diffuse GIM(162). This was externally validated by the same 
group and for a diagnosis of OLGIM III/VI, the AUC was 0.96 (95% confidence interval 0.93-
0.98). This endoscopic grading of GIM (EGGIM) was 89% sensitive and 95% specific for a 
risk stratification of moderate to severe GIM if a cut off score of >4 was used (186). On this 
basis, it could be argued that endoscopic staging with HR WLE plus NBI is sufficiently 
accurate for diagnosis and staging. This is an area of active future research.  
 
Gastric dysplasia and early gastric cancer 
 
Detection of gastric dysplasia and early gastric cancer is notoriously difficult due to the often 
only subtle findings and the lack of well-defined endoscopic appearances under white light 
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inspection.  Features commonly described, but not exhaustive, include: differences in colour 
(i.e., more red or pale); loss of vascularity, slight elevation or depression, nodularity, 
thickening, and abnormal convergence or flattening of folds(187,188). 
 
Therefore, optimal clearing of mucous and secretions is essential to allow for continuous and 
meticulous search of areas with features different from the surrounding mucosa(189,190). 
 
Recourse to chromoendoscopy with indigo carmine solution (0.2%) or virtual 
chromoendoscopy (NBI, FICE, i-Scan, BLI) is commonly advocated to enhance contrast and 
visualization of areas of concern or mucosal abnormalities. Areas of dysplasia may present 
throughout the stomach, with a slight predominance in antrum and along the lesser curvature, 
and can vary in size from a few millimeters to several centimeters. 
 
Gastric dysplasia can be morphologically classified into: adenomatous (intestinal), which 
includes adenomatous polyps; foveolar (gastric); and hybrid type(47,191). Compared to the 
adenomatous type, the foveolar type appears to be more commonly associated with high grade 
dysplasia(47,192). Endoscopically, these lesions are usually detected as 0-Is, 0-IIa or 0-IIc 
types according to the Paris classification of superficial neoplastic lesions(189). 
 
Adenomatous dysplasia is more likely to occur in the gastric body and lesser curvature of the 
stomach, whereas foveolar dysplasia is more typically located in the gastric antrum and incisura 
angularis. In addition, foveolar type lesions are smaller, often reddish in colour and present as 
flat or depressed areas more frequently than the adenomatous type(47). 
 
 
6.2.4 Biopsy strategy for diagnosis and risk stratification of the pre-malignant stomach 
 
What biopsy strategy should be adopted for the sampling and reporting of the pre- and early 
malignant stomach?  
Should all those undergoing routine endoscopy be biopsied or are there groups to target? 
 
 
We recommend that patients with image-enhanced features of chronic atrophic gastritis 
should undergo biopsies for confirmation of endoscopic diagnosis; biopsies are directed 
at mucosal sites within Sydney protocol areas where enhanced imaging reveals gastric 
intestinal metaplasia. Biopsies are collected in separate containers and labelled as either 
‘directed' or ‘random’ to corroborate endoscopic staging assessment (Evidence level: 
low quality; Grade of recommendation: strong; Level of agreement: 93%) 
 
We suggest that a baseline endoscopy with biopsies should be considered in individuals 
50 years and over, with laboratory evidence of pernicious anaemia, defined by vitamin 
B12 deficiency and either positive gastric parietal cell or intrinsic factor antibodies. As 
atrophy affects the corpus in pernicious anaemia, biopsies should be taken from the 
greater and lesser curves (Evidence level: low quality; Grade of recommendation: weak; 
Level of agreement: 93%) 
 
Biopsies should be undertaken in patients with endoscopic suspicion of GA, GIM, or early 
neoplasia. 
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Current surveillance protocols stipulate random biopsies in specified locations according to the 
updated Sydney protocol (Fig 5). However, random sampling does not reliably foster 
correlation of endoscopic and histopathologic findings and carries a risk of sampling error. By 
contrast, ‘directed’ biopsies of mucosal foci suspicious for GIM in areas of the updated Sydney 
protocol will drive quality control and ultimately propel endoscopy-led staging and risk 
stratification. This targeted biopsy strategy links endoscopic GIM detection with the well-
established OLGIM histopathologic classification scheme. The aforementioned numeric 
endoscopic classification system for staging of GIM has been shown to correlate strongly with 
OLGIM and with the extent of GIM (150), further supporting this change in practice. The GDG 
however did not agree on whether OLGA or OLGIM should be routinely used, principally 
because there is currently insufficient expertise or capacity for this to be routinely undertaken. 
Individual units however may choose to adopt this risk stratification system. 
 
 
 
6.3 Surveillance 
 
Should individuals with gastric pre-malignant lesions undergo surveillance? 
 
We recommend endoscopic surveillance every 3 years should be offered to patients 
diagnosed with extensive gastric atrophy or gastric intestinal metaplasia defined as that 
affecting the antrum and body (Evidence level: low quality; Grade of recommendation: 
strong; Level of agreement: 100%) 
 
We do not recommend surveillance in patients with gastric atrophy or gastric intestinal 
metaplasia limited just to the gastric antrum, unless there are additional risk factors 
such as a strong family history of gastric cancer or persistent H. pylori infection, then 
we suggest 3 yearly surveillance. (Evidence level: low quality; Grade of recommendation: 
strong; Level of agreement: 93%) 
 
We recommend patients with non-visible low-grade dysplasia should undergo an 
immediate second endoscopy with enhanced imaging and extensive biopsy sampling, 
followed by a repeat endoscopy within 1 year if no visible neoplasia is detected. If there 
is persistent, non-visible low-grade dysplasia, endoscopy should be repeated annually 
thereafter. (Evidence level: low quality; Grade of recommendation: strong; Level of 
agreement: 100%) 
 
We recommend patients with non-visible high-grade dysplasia should undergo an 
immediate second endoscopy with enhanced imaging and extensive biopsy sampling. 
We recommend on-going surveillance at 6-monthly intervals for persistent, non-visible 
high-grade dysplasia. High-grade dysplasia should be discussed at the regional upper 
GI cancer MDT and referred to a clinician with the appropriate expertise. (Evidence 
level: low quality; Grade of recommendation: strong; Level of agreement: 100%) 
 
6.3.1 Surveillance of chronic atrophic gastritis 
 
As the neoplastic cascade follows a multistep process from H. pylori-associated gastritis 
through GA and GIM to dysplasia (193), it follows that surveillance of a high-risk population 
may lead to the detection of early gastric cancer. Furthermore, the evolution of endoscopic 
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techniques such as ESD with 5 year disease free survival rates of 99% (194), further supports 
the detection of early gastric cancer through surveillance.  
 
There are several factors which influence the risk of progression to cancer including the extent 
of atrophy and GIM and a family history of gastric cancer. A strong family history is defined 
as those with a first degree relative or two or more second degree family members with 
histologically proven gastric adenocarcinoma. Those at the highest risk with GIM in the antrum 
and corpus have a 9.8% cumulative 5 year incidence of cancer (26). 
 
 
Outcomes of endoscopic surveillance of pre-malignant conditions 
 
There are no randomised controlled studies on the utility of GIM surveillance. There are 
however observational data. A small UK study assessed the effect of endoscopic surveillance 
of patients with GIM (specifically type III, incomplete GIM) every 6 to 12 months over a 12 
year period. Of the 26 patients surveyed, 11 developed gastric adenocarcinoma which were 
limited to the mucosa or submucosa at the time of detection. Although 4 patients were lost to 
follow up, when compared to the unit as a whole, the proportion of early cancers was much 
greater in surveillance patients (195). 
 
In a second study 166 patients with GIM, dysplasia, GA, ulcers, or polyps were surveyed over 
10 years and compared to 1753 open access endoscopy patients. Compared to the open access 
group, there were more stage I/II cancers (76% vs 23%) and an improved 5 year survival (50% 
vs 10%) in the surveillance group. 93 of the surveillance patients had GIM of whom 10 
developed gastric adenocarcinoma. In patients with GA and GIM the risk of malignancy was 
11% (196).  Both the aforementioned studies however were conducted before the advent of 
high resolution and image enhanced endoscopy, which makes it difficult to extrapolate to 
current practice. 
 
A northern European study in low incidence gastric cancer areas, surveyed 279 patients with 
GA, GIM or dysplasia over a mean period of 57 months. 1.4% (4 patients) were diagnosed 
with high-grade dysplasia or gastric cancer, of which 2 were successfully treated by ESD and 
2 by gastrectomy. All 4 patients who progressed had extensive GIM as defined by the OLGIM 
stage. None of those with limited AG or GIM progressed. The overall risk of neoplastic 
progression was 0.3% per year (197). 
 
There are a number of studies evaluating surveillance in pernicious anaemia and body-
predominant atrophic gastritis, however only one study has demonstrated the development of 
GC in 2/56 patients at the time of a surveillance endoscopy, three years after the initial 
endoscopy. 
 
The MAPS (Management of precancerous conditions and lesions in the stomach) guidelines 
published in 2012 recommend that patients with extensive GA and/or extensive GIM should 
be offered endoscopic surveillance every 3 years (10). MAPS also recommends that patients 
with mild to moderate atrophy or GIM limited to the antrum do not need follow-up.  
 
Cost effectiveness of endoscopic surveillance of pre-malignant conditions 
 
The early studies examining the cost effectiveness of CAG surveillance have shown conflicting 
results, which is partly due to the widely ranging variation in prevalence and progression to 
 34 
cancer.  Modelling undertaken by Yeh et in 2010 in a US population found surveillance to be 
cost effective for men over 50 years with dysplasia treated by EMR with annual surveillance 
(Cost per QALY was US$39,800), although for 10 yearly surveillance in those with any GIM 
(US$544,500) (198). A more recent cost-utility economic analysis in a European population 
between 50 and 75 years of age aimed to assess the cost effectiveness of endoscopic screening 
of the pre-malignant stomach using Markov modelling (199). The primary outcome was the 
incremental cost-effectiveness ratio (ICER) of a 3-yearly endoscopic surveillance versus no 
surveillance. Endoscopic surveillance every 3 years provided an ICER of € 18,336, well below 
the adopted threshold of € 36,575 corresponding to the proposed guideline limit of $ 50,000. 
Moreover, robustness analysis showed that in 78% of examined scenarios the model was cost-
effective. 3 yearly surveillance was found to be more cost effective than 5-10 yearly strategies. 
Two further studies from low to intermediate risk populations in Singapore utilising Markov 
modelling and cost-utility analysis, found 1 and 2 yearly surveillance were cost effective, 
although 3 yearly intervals were not analysed (200,201). In conclusion, recent cost 
effectiveness models support surveillance in CAG in low to intermediate risk populations 
between 1 and 3 yearly. These models did not investigate those with extensive CAG where the 
risk of progression is greater and thus the cost effectiveness is likely to be superior. 
 
As the cancer risk of focal intestinal metaplasia of the cardia is poorly defined and appears 
much lower than short segment Barretts oesophagus we do not recommend surveillance in this 
group(43).     
 
Summary 
Although there is a lack of randomised data on the survival benefits of surveillance for GIM, 
there is a moderate evidence base demonstrating progression of pre-malignant conditions, 
particularly extensive GIM to gastric adenocarcinoma and evolving data from surveillance 
studies. The cost effectiveness data is also compelling. We do accept however, as with 
surveillance of Barretts oesophagus, surveillance of GA and GIM will remain controversial. 
We recommend a surveillance interval of 3 years for those patients with extensive GA or GIM 
defined as that affecting the antrum and body. However, surveillance may not be appropriate 
for all patients with extensive atrophy and GIM, particularly the very elderly and those with 
multiple comorbidities where the benefit of surveillance may be offset by the risks of diagnostic 
endoscopy. For those with GA or GIM limited to the antrum, but with additional risk factors 
such as a family history of gastric adenocarcinoma and persistent H. pylori infection, we also 
recommend a surveillance interval of 3 years. Persistent H.pylori infection is defined as that 
refractory to treatment. We also suggest where possible, as with Barrett’s oesophagus 
surveillance, endoscopy is undertaken on a dedicated screening list. The remit of these 
guidelines do not cover the management of Hereditary Diffuse Gastric Cancer (63).   
 
6.3.2 Surveillance of dysplasia 
 
Although the risk of progression of dysplasia to gastric adenocarcinoma varies between studies, 
it is clear that HGD confers a greater risk of progression than LGD. 30 % and 85% of patients 
with HGD progress to cancer with follow up periods of up to 5 years with an estimated annual 
incidence of 6% (25,44). The overall risk of malignancy for LGD (combining mild and 
moderate dysplasia, as described in earlier classification systems) varies from 0% to 33% over 
follow up periods of up to 66 months (202–208). Two of the more recent observational studies 
have shown progression rates of between 3% and 9% (204,205). 
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Dysplasia in random biopsies also appears to increase the risk of cancer possibly by as much 
as 6% per annum(15,25). It is important to note that in those patients found to have incidental 
HGD or cancer by random biopsies on the index endoscopy, 80% will have a detectable lesion 
by virtual chromo-endoscopy (209). A finding of gastric dysplasia also carries a high risk of 
synchronous gastric adenocarcinoma, with rates as high as 30% in some studies (210). 
 
The histopathological biopsy diagnosis may not be representative of the final histopathological 
grade on excision. This has been described in a meta-analysis of 16 studies including over 
3,000 patients. Of patients initially diagnosed with LGD on biopsy, 25% were subsequently 
diagnosed with more advanced lesions after endoscopic resection (211). Of these 16.7% were 
HGD and 6.9% were invasive lesions. A Korean series demonstrated a similar upgrade of 
diagnosis from LGD in 18.7% of cases (212). Thus, the rate of under diagnosis is not 
insignificant. These data however are discordant with the lower documented progression rates 
in larger series of up to 9%. The authors found that lesion size larger than 2 cm, surface 
depression, absence of whitish discoloration, the presence of spontaneous bleeding, and 
nodularity on endoscopic examination were the major risk factors associated with a higher 
histopathological grade on excision (211,212). In those patients who undergo surveillance, 
repeat or multiple biopsies appear to not substantially improve the accuracy of the initial 
diagnosis (213,214). 
 
Indefinite for dysplasia may also be under or over staged with up to 25% of cases upstaged to 
dysplasia or cancer(215,216). We therefore recommend patients with indefinite for dysplasia 
have a review by an expert pathologist and a repeat procedure with image enhancement. 
 
Based on the current body of evidence, there are clear grounds to support the endoscopic 
resection of visible LGD and HGD, providing the risk of endoscopic resection is justifiable in 
regards to the health and preference of the patient. We suggest surveillance for HGD and LGD 
only if resection is not possible or appropriate, or if the dysplasia is not visible, or is the 
preference of the patient. For patients with LGD undergoing surveillance we recommend 
surveillance intervals of 1 year with high quality systematic endoscopy. If biopsies are negative 
for dysplasia after 3 consecutive endoscopies, then consider 3 yearly surveillance. For those 
with HGD undergoing surveillance, we recommend a repeat high-quality endoscopy, repeated 
6 monthly thereafter. All visible dysplasia should be resected where appropriate. There are no 
cost-effectiveness studies on surveillance of either HGD or LGD and it is unclear for how long 
surveillance should be continued. For those patients found to have non-visible dysplasia on 
random biopsies we suggest an immediate systematic endoscopy with enhanced imaging, if 
necessary in an expert centre. 
 
6.3.3 Surveillance after EMR & ESD for dysplasia and early gastric cancer 
 
The risk of neoplastic synchronous or metachronous lesions as well as recurrence after gastric 
ESD or EMR is high and varies between 10% and 20% (217–220). Therefore endoscopic 
surveillance is necessary. This will allow further diagnosis of early neoplastic lesions which 
can then be removed endoscopically. There is little available data on the follow up interval, 
however most recurrences occur within the first year after resection (217,221–224). We suggest 
therefore that a follow up endoscopy is undertaken 6 months after ESD or EMR of neoplasia 
and if no lesions identified, annually thereafter. This is in line with the Japanese and ESGE 
guidelines (225–227).  
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6.4 Treatment: Endoscopic therapy 
 
What lesions are amenable for endoscopic removal?  
How should these lesions be removed?  
Are there criteria on histopathological assessment that determine prognosis and follow up? 
 
We recommend that all gastric dysplasia and early gastric adenocarcinoma should be 
resected in an en-bloc fashion (EMR technique can achieve en-bloc excision for lesions 
≤10mm in size but only ESD technique can ensure en-bloc excision for lesions >10mm in 
size) (Evidence level: high quality; Grade of recommendation: strong; Level of agreement: 
100%) 
 
We recommend that complete (R0) endoscopic resection of gastric dysplasia and early 
gastric adenocarcinoma with the following features should be considered as curative: 
1) Low-grade dysplasia 
2) High-grade dysplasia 
3) Well or moderately differentiated intramucosal adenocarcinoma, irrespective of size 
and without ulceration 
4) Well or moderately differentiated intramucosal adenocarcinoma, <3.0 cm in size if 
ulcerated 
5) Well or moderately differentiated submucosal adenocarcinoma, <3.0 cm in size, with 
superficial submucosal invasion (Sm1; <500 micron submucosal invasion as measured 
in a straight line from the deepest fibre of the muscularis mucosae) 
6) Poorly differentiated intramucosal adenocarcinoma, ≤2.0 cm in size 
(Evidence level: moderate quality; Grade of recommendation: strong; Level of agreement: 
93%) 
 
The histopathological features of early gastric adenocarcinoma associated with a higher 
risk of lymph node metastasis after endoscopic resection include: 
1) Poorly differentiated submucosal, cancer irrespective of invasion depth below 
muscularis mucosae 
2) Signet ring cancer 
3) Lympho-vascular invasion 
4) Depth of submucosal invasion ≥500 microns as measured in a straight line from the 
deepest fibre of the muscularis mucosae 
(Evidence level: moderate quality; Grade of recommendation: strong; Level of agreement: 
93%) 
 
We suggest that where possible, all cases considered for resection should be discussed in an 
MDT with the appropriate expertise including pathologists and therapeutic endoscopists. 
When there is no local expertise, patients should be referred to an expert centre. Before any 
therapeutic procedure is undertaken, the risks and benefits of endoscopic resection and 
surgery should be discussed with the patient to aid their decision making. 
 
These recommendations apply to the intestinal type of gastric cancer as defined by the Lauren 
Classification(228,229). Diffuse type adenocarcinoma carries a worse prognosis than intestinal 
type that appears independent of the T and N stage(229).  
 
The risk of lymph node metastasis (LNM) underpins endoluminal therapy for early gastric 
adenocarcinoma. This risk has to be weighed against the significant risk of morbidity and 
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mortality following surgical resection. Endoscopic resection has become the organ-preserving 
treatment of choice for superficial gastric neoplastic lesions, because of the low risk of LNM 
that these lesions portend.  In a large series from the Far East Gotoda et al reviewed the 
prevalence of LNM in 5265 gastrectomy specimens. On multivariate analysis they found that 
none of the 979 non-ulcerated lesions had LNM. Additionally, they found that none of the 145 
well or moderately differentiated adenocarcinomas measuring less than 30mm, those with 
submucosal invasion of less than 500 microns (Sm1), and those without lympho-vascular 
invasion revealed LNM (230). This supported the initial Japanese guidelines on the indication 
criteria for endoscopic resection of early gastric adenocarcinoma, which included: intestinal 
type adenocarcinoma, endoscopically diagnosed intramucosal cancer, lesion size of ≤20mm 
and non-ulcerated lesions (226). In a second large series Hirasawa et al reviewed 3843 patients 
who underwent gastrectomy with lymph node dissection for poorly differentiated 
adenocarcinoma. On multivariate analysis they found that lesion size of > 20mm, lympho-
vascular invasion, and submucosal involvement were independent risk factors for LNM (231).  
 
Overall the two large series on surgically resected early gastric cancer demonstrate that the risk 
of LNM of superficial lesions is small (less than 1%) if the following criteria are met: 
 
1) Well or moderately differentiated intramucosal adenocarcinoma, irrespective of 
size and without ulceration 
2) Well or moderately differentiated intramucosal adenocarcinoma, ≤3.0 cm in size 
if ulcerated 
3) Well or moderately differentiated submucosal adenocarcinoma, <3.0 cm in size, 
with superficial submucosal invasion (Sm1; <500 micron submucosal invasion as 
measured in a straight line from the deepest fibre of the muscularis mucosae) 
4) Poorly differentiated intramucosal adenocarcinoma, <2.0 cm in size 
 
This led to the adoption of the expanded indications for ESD of early gastric cancer. The 
expanded criteria however should not be taken as absolute, particularly where the balance 
between risk and benefit of surgery is less clear. The original definition of early gastric cancer 
was defined in 1971 by The Japanese Society of Gastroenterology and Endoscopy as a 
carcinoma limited to the mucosa and/or submucosa regardless of the lymph node status. This 
has recently fuelled much controversy as the survival of early gastric cancer is closely 
associated with the risk of lymph node metastasis. We have therefore adopted the definition of 
adenocarcinoma limited to the mucosa and superficial submucosa (Sm1; <500 micron), as that 
amenable to endoscopic resection. 
 
 
Two recent series, one from the Far East and one from the West, assessed the outcomes of the 
extended indications. The series by Hasuike et al included 470 lesions, of which 466 (99.1%) 
were resected en bloc and the curative resection rate 67.4% (232). A similar Western series 
reported that en bloc resection was achieved in 81/91 lesions (89.0%) and curative resection 
was achieved in 67/91 lesions (73.6%) (233). The risk of perforation in both series was reported 
to be up to 2.6%. However, the risk of delayed bleeding was lower in the Western series (2.2% 
compared to 6.2%). The higher curative resection and lower delayed bleeding rate in the 
Western series is encouraging, although the number of treated lesions was smaller.  
 
Patient selection is key in achieving favourable outcomes with ESD for early gastric cancer. 
Patients who do not meet the expanded criteria for a curative outcome following gastric ESD 
are referred for radical surgery. In a multicentre retrospective study Hatta et al developed a 
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risk-scoring system using multivariate logistic regression analysis of 1101 patients who had 
undergone radical surgery after failing to meet the criteria for curative endoscopic resection of 
early gastric cancer (234).  Following this, they validated the scoring system in a further  905 
patients. They demonstrated that the scoring system known as ‘eCura system’ (Table 6) 
predicted cancer-specific survival in this cohort of patients. This scoring system is promising 
but will require further validation in other centres. 
 
 
Risk factors Points 
Lymphatic invasion 3 
Lesion size >30mm 1 
Positive vertical margin 1 
Venous invasion 1 
Submucosal invasion ≥500 μ m 1 
Table 1: Weighted scores for risk factors 
 
Lymph Node 
Metastasis (LNM) 
Risk Groups 
Points Risk of  LNM 
(%) 
Cancer specific 
5-year survival 
(%) 
Low 0-1 2.5 99.6 
Intermediate 2-4 6.7 96.0 
High 5-7 22.7 90.1 
Table 6: eCura system 
 
 
EMR (cap-assisted) was the initial technique used to resect superficial gastric neoplasia. 
However, this technique is unable to effectively resect lesions larger than 10mm en bloc. In a 
recent meta-analysis comparing the efficacy of gastric ESD and EMR, the en bloc and R0 
resection rates of EMR were found to be 51.7% and 42.4% (235).  This in turn is associated 
with local recurrence rates as high as 30% (194,217,221,236–239).  However, in a subgroup 
analysis of lesions smaller than 10-15mm, it was noted that there was no difference in survival 
regardless of the endoscopic resection technique. 
 
ESD was a technique developed to overcome the shortcomings of gastric EMR enabling the en 
bloc resection of lesions larger than 10mm. In a large series from the Far East of 1033 early 
gastric cancer lesions, Oda et al reported an en bloc resection and R0 resection rate of 98% and 
93%, respectively (240). Three meta-analyses comparing the outcomes of EMR and ESD 
showed that ESD achieved higher en bloc resection rates (92% vs. 52%; odds ratio [OR] 9.69, 
95%CI 7.74–12.13), histopathologically complete resection rates (82% vs. 42%; OR 5.66, 
95%CI 2.92–10.96) as well as lower recurrence rates (1% vs. 6%; OR 0.10, 95%CI 0.06–0.18) 
(235,241,242).   
 
The current Japanese Gastroenterological Endoscopy Society and European Society of 
Gastrointestinal Endoscopy guidelines recommend that ESD is the treatment of choice for most 
superficial gastric neoplastic lesions (225,243). However, ESD is a technique that is in its infant 
stages in the West and the complication rates during early adoption can be high. In one 
European series of 75 patients who underwent gastric ESD en bloc resection was achieved in 
85.3% and R0 resection was achieved in 84.0%. However, the complication rate which 
included delayed bleeding and perforation was as high as 24% (244). Finally, it should be noted 
that signet ring cancer is not currently recommended for endoscopic resection. However, there 
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will soon be published prospective data on the treatment of these lesions with ESD if they are 
less than 20mm which may alter this management strategy.  
 
In summary we recommend where appropriate endoscopic resection as first line therapy for all 
early gastric neoplasia in line with the Japanese extended indications, favouring ESD over 
EMR for larger lesions due to the superior R0 resection rate. Surgery should only be undertaken 
when endoscopic resection is not considered curative or is the preferred patient option. 
 
6.5 Treatment: Pharmacological 
 
Is there a role for other pharmacological therapies e.g. COX inhibitors and anti-oxidants? 
 
We do not recommend the use of NSAIDs or cyclooxygenase (COX) 2 inhibitors to 
reduce the risk of progression of pre-malignant lesions of the stomach.  (Evidence level: 
Moderate; Grade of recommendation: Strong; Level of agreement 100%) 
 
We do not recommend the use of antioxidants as a means to reduce the prevalence of 
pre-malignant gastric lesions. (Evidence level: Moderate; Grade of recommendation: 
Strong; Level of agreement 100%) 
 
 
6.5.1 NSAIDs, aspirin & COX-2 inhibitors 
 
There are numerous examples of chronic inflammatory conditions that predispose to cancer 
development. Meta-analyses and retrospective studies have demonstrated that there is a lower 
incidence of gastric cancer associated with regular, long-term use of NSAIDs including aspirin 
(245–247). These are thought to reduce carcinogenesis by inhibiting cancer-associated 
prostaglandins, cytokines, and angiogenic factors. However, their use has been limited by their 
other gastrointestinal side-effects and there is little in the way of good quality, prospective trials 
to determine whether they can prevent the progression of pre-malignant gastric lesions. 
 
As such, attention has turned to cyclooxygenase-2 (COX-2) inhibitors with trials particularly 
focusing on the use of rofecoxib, etodolac, and celecoxib. However, there is limited evidence 
to support their use because of low quality studies, performed in heterogeneous populations in 
high gastric cancer incidence countries . There is one placebo-controlled randomised control 
trial. This trial explored the use of rofecoxib in reversing GIM in those cleared of H. pylori. It 
demonstrated that there was no evidence that rofecoxib causes a regression in GIM over a two-
year period (248). Amongst the low-quality trials a study using etodolac on patients who 
underwent endoscopic early cancer resection found a higher rate of metachronous cancer 
lesions in those treated with the COX-2 inhibitor (249). Only celecoxib has been suggested to 
provoke regression of gastric pre-malignant lesions, however, in general these trials are limited 
to small patient numbers over short periods of time (250–252). A large Swedish population-
based case-control study comparing 567 incident cases of gastric cancer and 1165 controls 
found that aspirin users had a moderately reduced risk of cardia and non-cardia gastric cancer 
(OR 0.7; 95% CI = 0.6-1.0), although NSAID use had no protective effect in this study (253). 
A recent literature review of 24 studies suggested that both aspirin and NSAIDs reduce the risk 
of gastric cancer with a RR of 0.7 (95%CI=0.62-0.80) and 0.86 (95%CI=0.80-0.94), 
respectively (254). The dose-response analysis indicated that the risk decreased by 11% and 
5% for 2 years after a dose increment for both. 
 
 40 
Further work is undoubtedly required to address the potential of celecoxib, aspirin, and 
NSAIDs in the chemoprevention of pre-malignant gastric lesions, in particular in well-
designed, randomised, long-term follow-up trials in populations who have a low incidence of 
gastric cancer. Any benefit must be weighed against the known gastrointestinal side effects of 
aspirin and NSAIDs. 
 
6.5.2 Antioxidants 
 
There are a limited number of trials exploring the use of anti-oxidants for chemoprevention of 
gastric premalignant lesions. Three studies have been performed, all in populations with a high 
incidence of gastric cancer and with generally disappointing results. Correa et al demonstrated 
some benefit with regards to histopathological outcome at 6-years following ascorbic acid and 
beta-carotene use, but this improvement was lost after 12-years (255) [9]. The other two studies 
did not demonstrate any benefit of using antioxidants in preventing the progression or causing 
regression of pre-malignant gastric lesions (256,257). 
 
 
 
6.6 Endoscopic screening for gastric adenocarcinoma 
 
Is there evidence to support the introduction of a population screening programme for 
glandular gastric cancer ? 
 
We suggest endoscopic screening should be considered in individuals aged 50 or older 
with multiple risk factors for gastric adenocarcinoma (males, smokers, pernicious 
anaemia), in particular in those with a first-degree relative with gastric cancer. 
(Evidence level: low quality; Grade of recommendation: weak; Level of agreement: 100%) 
 
We do not recommend endoscopic screening for gastric adenocarcinoma in the UK 
population (Evidence level: low quality; Grade of recommendation: strong; Level of 
agreement: 100%) 
 
The evidence addressing the effectiveness of endoscopic screening for prevention of gastric 
cancer has been garnered from studies conducted in high risk populations (defined as an age-
standardised rate (ASR) >20 per 100,000) in Japan and Korea (29.9 and 41.3 respectively) 
(258). These include 5 cohort studies and 3 case-control studies. Although there are no 
randomised control trials, the results of the available studies suggest a reduction in mortality 
from gastric cancer in screened populations. In the more recent regional Japanese cohort 
studies, there was a reduction in gastric cancer mortality (calculated as the standardised 
mortality ratio or adjusted relative risk) of 57% and 67% after a 5 and 6 year follow up (259–
261) The earlier cohort studies from Japan and China were less convincing but were limited by 
a broad age distribution and poorly matched cohorts (262,263). The results of the case-control 
studies were equally variable with a reduction in gastric cancer mortality of between 20% and 
80% in high-risk populations in Japan and South Korea (264,265). Based on these results, the 
authors recommended endoscopic screening in regions of high gastric cancer incidence. 
 
The test characteristics of endoscopic screening have been described in four studies. Hosokawa 
found the sensitivity of endoscopy to be 78% after comparing the gastric cancer incidence in 
those screened from a cancer registry (266). Similar sensitivities of 69% and 89% have been 
found across other cancer registries in Japan and South Korea (267–269). In the South Korean 
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study the gastric cancer detection rates was 2.61 per 1,000 screening endoscopies, with a 
specificity of 96% (267). 
 
There have been two studies in low incidence regions (defined as an ASR <10 per 100,000) 
such as the United States of America (3.9 per 100,000), assessing the cost effectiveness of 
endoscopic screening. The cost of a single screening endoscopy at the age of 50 in the general 
population was $115,664 per quality-adjusted life year (QALY), suggesting that endoscopic 
screening was not cost effective (198,270). Cost-effectiveness analyses in higher risk areas 
have demonstrated incremental cost-effectiveness ratios (ICER) of $44,098 and $25,949 per 
QALY for annual and biannual screening endoscopy, respectively (200). In a study in Taiwan 
where patients at the age of 50 who had low levels of pepsinogen-I (<30 ng/ml) were offered 
endoscopy the ICER was $29,741 per life year gained (271). 
 
A Markov model of screening in an intermediate risk population (age standardised rate of >10 
and <20 per 100,000 population) for ages 50 to 75 years found that upper endoscopy combined 
with screening colonoscopy (every 10 or 5 years) had an ICER of €15,407/QALY and 
€30,908/QALY, respectively(272). Stand-alone endoscopic screening (every five years) had 
an ICER of €70,693/QALY and pepsinogen screening an ICER of €143,344/QALY. This work 
suggests endoscopic gastric cancer screening in conjunction with a scheduled colonoscopy may 
be cost-effective in countries with intermediate gastric adenocarcinoma risk such as in Eastern 
Europe or Portugal. These results imply that resources allocated to endoscopic colorectal 
cancer screening programs could be used to provide gastric cancer screening, both for detection 
of high-risk individuals with extensive premalignant conditions and early gastric cancer 
patients.  
 
Although there is insufficient evidence to support screening in low risk populations, a recent 
study by Bodger and colleagues demonstrated wide variations in rates of elective gastroscopy 
within general practice populations. They showed that oesophago-gastric cancer patients 
belonging to practices with low rates of gastroscopy were at increased risk of poor outcome 
oesophago-gastric cancer. However, if the low referral practices increased to the mid referral 
range the crude cost per life-year saved for a hypothetical scenario is £140,000, well above a 
suggested threshold of £25,000. Therefore despite the poorer outcomes, given the high cost 
implications, primary care physicians should follow a restrictive referral practice (273).  
 
A recent retrospective nationwide Taiwanese propensity-matched cohort study evaluating the 
impact of non-screening gastroscopy on gastric cancer related mortality found that gastric 
cancer patients who had undergone gastroscopy in the 5 years before the diagnosis of gastric 
cancer had a better survival than patients who had never undergone a gastroscopy or whose 
last gastroscopy was more than 5 years before the diagnosis. The authors found that gastric 
cancer was detected at an earlier stage in patients who had recently undergone endoscopy. The 
risk of gastric cancer in this study population is low to moderate. This is the first study showing 
a significant survival advantage of recent endoscopy in gastric cancer patients in a region of 
low to moderate gastric cancer incidence (274). 
 
There are factors apart from the pre-malignant stomach that confer a greater risk of gastric 
adenocarcinaoma as described in section 6.1.2. These include family history, particularly those 
with first degree relatives, pernicious anaemia with an annual incidence of 0.27% in 
unsubstantiated cases, older age, males and smoking. Ethnicity is also related to an increased 
risk, but this may be due to a higher prevalence of H.pylori. In individuals within low risk 
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populations who have additional risk factors as described above, screening endoscopy may be 
of value. 
 
In summary, we suggest only those with multiple risk factors for gastric cancer are considered 
for screening gastroscopy from the age of 50. If the gastroscopy is normal, then we would not 
recommend any further screening. Where CAG is diagnosed, this guideline should be followed. 
 
6.7 Diagnosis and management of epithelial gastric Polyps 
 
What are the epithelial gastric polyps and how should they be managed ? 
 
We recommend that the number of gastric polyps (or estimated number), location of 
polyps, and size of largest polyp should be clearly documented (Evidence level: low 
quality; Grade of recommendation: strong; Level of agreement: 100%) 
 
We recommend that gastric polyps other than fundic gland polyps should be biopsied 
(Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 100%) 
 
We recommend that photo-documentation should be undertaken for all polyps or 
representative polyps if numerous (Evidence level: low quality; Grade of recommendation: 
strong; Level of agreement: 100%) 
 
We recommend that if adenomas or hyperplastic polyps are present, the background 
mucosa should be endoscopically assessed for gastric atrophy, intestinal metaplasia, H. 
pylori, and synchronous neoplasia (Evidence level: moderate quality; Grade of 
recommendation: strong; Level of agreement: 100%) 
 
We recommend that all adenomas should be resected when clinically appropriate and 
safe to do so (Evidence level: low quality; Grade of recommendation: strong; Level of 
agreement: 100%) 
 
We recommend that a follow up gastroscopy should be performed at 12 months after 
complete endoscopic excision of adenomas with on-going surveillance gastroscopy 
annually thereafter when appropriate (Evidence level: low quality; Grade of 
recommendation: strong; Level of agreement: 93%) 
 
We suggest that hyperplastic polyps >1cm, pedunculated morphology, and those 
causing symptoms (obstruction, bleeding) should be resected. If present H. pylori should 
be eradicated prior to re-evaluation for endoscopic therapy (Evidence level: low quality; 
Grade of recommendation: weak; Level of agreement: 100%) 
 
We suggest enhanced endoscopic imaging is used to aid characterisation of gastric 
polyps when there is diagnostic uncertainty following white light examination (Evidence 
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level: low quality; Grade of recommendation: weak; Level of agreement: 93%) 
 
The scope of the guidelines is restricted to epithelial polyps and thus neuroendocrine tumours 
and sub-epithelial polyps have been excluded. Gastric epithelial polyps can be mainly 
classified in 3 types (107), fundic gland polyps, hyperplastic polyps and adenomatous polyps 
 
6.7.1 Fundic gland polyps 
Fundic gland polyps (FGPs) are the most prevalent type of gastric polyps (13-77%) (275) 
(276). They are typically multiple, small (<1cm), and located in the fundus and corpus. At 
endoscopy they appear pale, smooth, glassy, and transparent or translucent (Fig 7). Their colour 
is either lighter or the same colour as the surrounding mucosa. Lacy blood vessels are seen 
through the translucent surface and the surface shows a pattern of fine grey dots. On enhanced 
imaging such as NBI, FICE or iScan the surface architecture becomes more prominent. FGPs 
are usually not associated with an increased risk of cancer, unless in the context of familial 
adenomatous polyposis syndrome (FAP). However, larger FGPs over 1 cm have been shown 
to be dysplastic in 1.9% and contain focal cancer also in 1.9%. Fundic gland polyps are 
associated with long-term PPI use and can spontaneously regress following PPI discontinuation 
(277). There is no association with background H. pylori infection or gastritis. 
 
Management of fundic gland polyps 
Number, location, morphology, and the size of the largest polyp should be documented. 
Representative pictures of the polyps should be taken. Diagnosis is easily made by endoscopic 
appearance as described above, but biopsy confirmation should be sought when in doubt. Large 
numbers of polyps (>20), young age (<40 yrs), dysplastic appearing polyps (where the typical 
surface and vascular architecture alters particularly when irregular), and the presence of 
duodenal adenomas, should lead to exclusion of FAP (107). Fundic gland polyps (FGP) do not 
require excision unless they have atypical features. Size >1 cm, antral location, ulceration, or 
an unusual appearance should question the diagnosis of FGP and lead to excision (278). 
Targeted biopsies should be taken where excision is not undertaken. Patients on long term PPIs 
should be revaluated for appropriateness of the PPI, dose of PPI, and alternative treatments 
(277). There is no role for surveillance gastroscopy for FGPs, except in the setting of FAP 
(107). 
 
6.7.2 Hyperplastic polyps 
Hyperplastic polyps constitute 18-70% of all gastric polyps, are usually single or few in number 
and are more frequently observed in the antrum or adjacent to ulcers, stomas and gastrectomy 
sites. They appear as smooth, red buttered with whitish exudates (fibrin) and are dome shaped 
(Fig 7). They are usually small (0.5–1.5 cm), but can be larger and present as lobulated and 
pedunculated masses covered with superficial erosions. They are typically associated with H. 
pylori gastritis (25%), GA and GIM. Regression generally occurs after eradication of H. pylori 
(up to 70%)(108). 
 
Gastric hyperplastic polyps can reveal dysplasia (1.9-19%) and malignant transformation (0.6-
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2.1%) (279) (280) (281), especially when larger than 1cm and in the post-gastrectomy stomach, 
(281–284). A dysplastic hyperplastic polyp is associated with an increased risk of synchronous 
neoplastic lesions in the surrounding mucosa of approximately 6% (285–291). 
 
Small, white and flat plaques in the fundus have the appearances of hyperplastic polyps with a 
foveolar pit pattern, but are areas of focal foveolar hyperplasia or more specifically hyperplasia 
of the foveolar epithelium (292). These have been described as multiple white flat lesion 
(MWFL) and appear to be more prevalent in those taking PPIs. Histologically, the biopsy 
specimens from the MWFL included fundic gland parietal cell protrusions and oxyntic gland 
dilatations. There was no evidence of intestinal metaplasia(293). 
 
Management of hyperplastic polyps 
Diagnosis of hyperplastic polyps and the absence of dysplasia should be confirmed by 
histology. The remainder of the stomach should be carefully evaluated for synchronous 
neoplasia, degree and extent of GA and H. pylori. H. pylori eradication should be considered 
in all cases prior to endoscopic resection as many polyps will regress with a repeat endoscopy 
3-6 months after eradication (108). Polyps >1cm, pedunculated polyp morphology, or 
symptomatic polyps (obstruction, bleeding) should be completely resected (282,294). Even 
when H. pylori is present, those polyps >3cm should always be resected as the risk of dysplasia 
and cancer is high (281,294). Endoscopic surveillance is recommended to monitor the risk of 
further gastric neoplasia where there is evidence of dysplasia, GA or GIM. The endoscopic 
surveillance interval should be determined by the stage of CAG. 
 
6.7.3 Adenomatous polyps 
Adenomatous polyps are usually single (82%), small (<2cm), and located in the antrum and 
incisura angularis. Endoscopically they have a velvety pink lobulated appearance and can be 
sessile or pedunculated. In Western countries their prevalence varies between 0.5 and 10% 
(295)(278). They are normally associated with a background of GA and GIM. Coexistence of 
a synchronous gastric adenocarcinoma has been found in up to 30% of patients with an 
adenomatous polyp. Moreover, 50% of adenomatous polyps larger than 2cm contain foci of 
adenocarcinoma (296)(210). 
 
Management of Gastric adenomas 
Gastric adenomas carry a significant risk of progression to cancer and should be resected where 
appropriate. Diagnosis of adenoma and degree of dysplasia should be histologically confirmed 
before treatment is undertaken. A careful evaluation of the stomach should be carried out to 
identify synchronous neoplasia (30%), GA and GIM. Endoscopic resection is the preferred 
mode of treatment. An en-bloc excision with ESD is advisable for sessile polyps > 15mm (225) 
as the possibility of invasive neoplasia in the adenoma is high and ESD reduces the risk of 
recurrence compared to EMR. A follow up gastroscopy should be performed at 6-12 months 
after endoscopic resection of adenomas. Patients with adenomas should continue to have 
surveillance gastroscopy at yearly intervals where appropriate, depending on the number of 
polyps, their size, and highest grade of dysplasia. 
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6.7.4 Optical diagnosis of gastric polyps 
 
Optical enhancement with technology including NBI (Olympus), iScan (Pentax) and FICE 
(Fujinon) with or without near focus or magnification allows interpretation of the mucosal 
surface achitectural patterns and vasculature. FGPs are characterised by small round pits and a 
honeycomb microvascular pattern (sensitivity 94.7%, specificity 97.4%), whereas hyperplastic 
polyps display prolonged or villous pits and a dense vascular pattern (sensitivity 93.6%, 
specificity 91.6%), respectively (297).  The NBI features of gastric adenomas have not been 
well defined, although a paler colour relative to the background mucosa and a slit-like crypt 
opening and regular white opaque substance, which corresponds to absorbed subepithelial lipid 
droplets, are often observed. The brown colour on NBI is due to the subepithelial vessels, which 
are obscured by lipid droplets accumulated above the subepithelial vessels. A tubular, villous 
or ridged mucosal structure is generally observed as with colonic adenomas (153,298,299). 
 
Based on the NICE classification validated for colon polyps, a modified NBI classification 
system has been recently proposed in a retrospective evaluation by two expert reviewers to 
reliably diagnose low risk gastric polyps (FGPs or hyperplastic polyps < 1cm) with the aim of 
eliminating the need for biopsy (300). 
Relative to the background mucosa, polyps were divided in two groups: 
1) Lighter or same colour 
2) Darker 
“Lighter or same colour” polyps were further subdivided according to their vascular network 
in: 
a) Isolated vessels 
b) No vessels 
c) Brown vessels surrounding white structures 
 
Polyps with same or lighter colour and with no vessels or isolated lacy vessels were FGPs in 
97-100%. Polyps lighter or similar in colour compared to background mucosa with a 
homogenous absence of surface pattern were FGPs in 94-100%. The sensitivity and specificity 
for lacy vessels was 61-66% and 93-96%, respectively, for optical FGP diagnosis. If a lesion 
had either isolated lacy vessels or homogeneous absence of pattern the NPV for gastric 
adenoma or cancer was 100%. The NPV for colour same or lighter than background mucosa 
was 96-97%. Polyps with lighter or same colour as the background mucosa, but larger than 
1cm or showing brown vessels surrounding white structures, or those darker in colour require 
biopsy. Although useful as a research algorithm for assisting decision making, further studies 
and validation of this classification are required.  
 
All polyps where the mucosal pattern is disorganised, irregular, or absent (amorphous) are 
suspicious for neoplasia. Likewise, enhanced or irregular vascular patterns are suspicious for 
neoplasia and targeted biopsies should be taken. 
 
In summary, image enhanced endoscopy (IEE) improves the visualisation of gastric polyps and 
allows diagnosis of FGPs. Diagnosis of hyperplastic polyps and adenomas with IEE is less 
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clear, but may aid in the diagnosis of HGD or cancer. We therefore have suggested that IEE is 
used in all polyps to aid diagnosis and direct biopsies. 
 
It is important to emphasize that the evidence base surrounding the detection, characterisation 
and management of gastric polyps was generated utilising lower resolution endoscopes and 
thus there is a need for further studies investigating the accuracy of optical and targeted 
histological diagnosis with newer endoscopes. Currently, the evidence supports endoscopic 
resection over biopsy of many non-fundic glandular polyps given the likelihood of upstaging 
neoplasia (301). This is of particular importance given the risks of bleeding associated with 
gastric polypectomy. 
 
7 Education, audit, and benchmarks and research 
 questions 
 
7.1 Audit and benchmarks 
 
The prevalence of GIM in patients undergoing endoscopy for dyspepsia is as high as 25% in 
European studies. The prevalence of GIM is influenced by ethnicity, infection rates with H. 
pylori, age, and family history of gastric cancer. GIM is present in 100% of intestinal type 
gastric cancer. Detection of GIM is therefore crucial as a first step in order to identify those at 
risk of gastric adenocarcinoma and may be an obvious benchmark as a quality standard for 
upper GI endoscopy. The prevalence of gastric atrophy in Western populations is lower than 
GIM and varies from 0-8% as previously described. We suggest a benchmark of 10 % detection 
rate for GIM and/or gastric atrophy in those patients undergoing investigation for upper GI 
symptoms.  
 
7.2 Education 
 
The miss rate for gastric cancer on endoscopy is high and current awareness of the endoscopic 
features of its precursors, GA, and GIM is low. We would suggest that knowledge in these 
pathologies is incorporated into the new national gastroenterology curriculum for higher 
training for gastroenterologists, surgeons, and pathologists. 
 
7.3 Service and cost implications of the guidelines 
 
An extensive service evaluation has not been conducted for this guideline. We have made an 
estimate of the likely additional work generated by adoption of the guidelines. As discussed, 
in Western populations (Europe and US) the overall prevalence of CAG in young males and 
females (below 55 years) was 0-8.3%. In older age groups (above 55 years) the prevalence was 
reported to be up to 13% (20) and in the EUROGAST study, below 5% (19) and 5.3% in those 
aged 55-64 years. Of the 1.7 million endoscopies performed per year in the UK approximately 
40% are upper GI procedures (302). Thus, in a unit performing a total of 10,000 procedures 
per year, 4000 will be upper GI endoscopies of which approximately 200 patients will have 
CAG. Assuming endoscopic diagnostic accuracy of 100% and a CAG prevalence of 5%, this 
will give rise to 200 additional sets of Sydney biopsies assuming the unit was not previously 
taking biopsy samples for CAG. This is likely to result in a repeat procedure in a proportion of 
cases where image enhanced endoscopy was not available during the initial endoscopy. There 
is no clear data to define the proportion of CAG that extensively affects the stomach and 
therefore requiring surveillance, but we have estimated this to be 40% of all CAG diagnosed 
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based on our own experience. We estimate that there will be 130 patients per unit requiring 
surveillance endoscopy between one and three yearly. 
 
7.4 Future Research 
 
This guideline aims to improve the standardisation of practice in the management of patients 
at risk of gastric adenocarcinoma. Within this we envisage that improved endoscopic quality, 
and consequently the detection of CAG and early gastric neoplasia, with targeted surveillance 
will improve the outcomes of gastric cancer. However, the impact of the guidelines on gastric 
cancer survival nationally is likely to be small, principally because only a small proportion of 
patients with gastric cancer will be detected by endoscopy at an early stage. Therefore, studies 
addressing cost effective, non-invasive, population based screening should be a research 
priority of the next 5-7 years. The other main priority is a measurable improvement in the 
quality of gastroscopy. 
 
 
Quality standards (QA) & improvement (QI) 
 We suggest that a quality improvement bundle for upper GI endoscopy requires 
derivation and assessment as a priority for research in order to improve diagnostic rates 
of early gastric neoplasia and its precursors (GA and GIM) 
 We suggest that quality indicators are required for systematic gastric surveillance 
endoscopy and photo-documentation 
 
Screening & surveillance 
 We suggest pilot studies for non-invasive population-based screening strategies for 
gastric cancer are a research priority 
 We suggest that a pilot study is required to assess the cost-effectiveness of endoscopic 
gastric cancer screening when combined with a screening colonoscopy 
 We suggest that further research is required to investigate the optimal surveillance 
strategy for CAG 
 
Diagnosis & staging 
 We suggest that the accuracy and reproducibility of optical diagnosis and staging of 
GA and GIM needs to be investigated in a multicentre study 
 We suggest research to determine whether the severity and distribution of CAG 
categorized by OLGA and OLGIM accurately reflect cancer risk during follow-up.  
 Cytosponge has been shown to detect cardia intestinal metaplasia (303), but more 
research is needed to see if this could be a tool to help pick up cardia IM as a triage to 
endoscopy. 
 We suggest that further research is required to investigate the risk of progression of 
histologically and serologically confirmed pernicious anaemia. 
 We suggest that the natural history and risk of progression to cancer of visible and non-
visible LGD requires further research. 
 
Prevalence 
 We suggest that further research is required to quantify more accurately the prevalence 
and extent of GIM in European endoscopy practice 
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9 Planned Review Date 
 
The guidelines should be considered for review in 5 years from the date of submission for 
publication estimated to be November 2023. 
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Figure captions BSG Guidelines 
 
Figure 1. 
Figure 1 | Normal gastric corpus and antrum mucosal surface pattern with white light, 
enhanced and magnification endoscopy. The round ‘pit patterns’ of the corpus (Ai) and 
elongated ‘pit patterns’ of the antrum (Di) can be seen without magnification or 
enhancement. In the corpus (Ai), the red collecting venules (CV) are evident as well as the 
round dark red crypt openings (CO). The vascular anatomy becomes more pronounced with 
NBI (Aii & Dii). The visible anatomical components seen on magnification NBI include the 
dark brown ‘pit openings’ (PO), the dark brown sub-epithelial capillary network (SECN), and 
the light brown marginal crypt epithelia (MCE). The corpus mucosa has dark round ‘pit 
openings’, surrounded by the lighter MCE, followed by the darker circular SECN (Aii & 
Aiii). In contrast, the dark, oblique ‘pit openings’ in the antrum are grooved so the light 
coloured ridged or villiform epithelium (MCE) surrounds the dark SECN, termed the ‘groove 
type pattern’ (Dii & Diii). The corresponding histopathological architecture can be seen in 
the corpus (B and C) and in the antrum (E and F). 
 
Figure 2. 
Figure 2 | Chronic atrophic gastritis (CAG) and the atrophic border on white light and image 
enhanced endoscopy. There are four principle endoscopic features of CAG: palor (A, B, C 
and D), loss of gastric folds (A, B, C and D), prominence of the vessels (A, B, C and D) and 
the atrophic border (A and B). The paler areas of atrophy are also clear on image 
enhancement (E and F). 
 
Figure 3. 
Figure 3 | The Integrated and Modified Kimura & Sydney Biopsy System. The modified 
Kimura staging system divides the extent of atrophy into antrum only (antral), antrum to 
incisura (antral dominant), antrum to lesser curve (corpus dominant), and antrum, lesser 
curve and greater curve (pan-atrophy). This system integrates Sydney protocol biopsies 
which should be taken from the antrum (site 1 and 2), incisura (site 3), lesser curve (site 4) 
and greater curve (site 5). The anatomical CAG boundaries and biopsy sites can be seen in 
the splayed (A) and cross-sectional cartoon (B) of the stomach. The biopsy sites defined in 
the endoscopic retroflexed (C) and forward view (D). 
 
Figure 4. 
Figure 4 | Gastric intestinal metaplasia under white light, image enhanced and magnification 
endoscopy. Intestinal metaplasia typically appears as small grey-white slightly elevated 
plaques surrounded by mixed patchy pink and pale areas of mucosa causing an irregular 
uneven surface (A). These appearances are more evident with image enhancement (B). 
Corpus GIM can be distinguished from the normal straight/tubular glands of the corpus by a 
‘groove type pattern’ similar to that of the antrum or villiform pattern of the intestine and 
may be appreciated with higher resolution technology on white light endoscopy (C and D). 
GIM in the antrum is more difficult to characterize as the normal glands are oblique. 
Additional features of GIM to aid diagnosis in the antrum include the light blue crest (LBC) 
and the marginal turbid band (MTB) (E). The LBC is a fine, blue-white line on the crest of 
the epithelial surface seen with NBI enhancement and is a highly accurate sign of the 
presence of intestinal metaplasia (see text). 
 
Figure 5. 
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Figure 5 | Fundic glandular and hyperplastic polyps. A) Fundic glandular polyps seen in the 
corpus and body. They are either lighter or the same colour as the surrounding mucosa. B) 
On near view, with image enhancement, lacy blood vessels are seen through the translucent 
surface and the surface shows a pattern of fine grey dots. C) Hyperplastic polyps are smooth, 
red buttered with whitish exudates (fibrin) and are dome shaped. The surface vascular pattern 
is more prominent on image enhancement (D). 
 
Figure 6. 
BSG Guidelines for the endoscopic management of chronic atrophic gastritis, gastric 
dysplasia and gastric epithelial polyps. 
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